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ABSTRACT 
 Exposure to hormones or endocrine disrupting chemicals (EDCs) can have many 
adverse effects on the endocrine system and can potentially lead to endocrine related 
adverse health effects such as reproductive dysfunction, obesity, and thyroid 
dysfunction. The pituitary gland plays a critical role in regulation of the endocrine axes; 
therefore, if EDCs affect the pituitary, it could lead to the development of endocrine 
related health effects. Exposure to EDCs during developmental windows is often more 
detrimental due to the perceived higher sensitivity and the potential for exposure to 
have lasting effects. Pituitary development occurs during two critical windows: 
embryonic and neonatal. During these periods, progenitor cells proliferate and 
eventually differentiate to one of three lineages. One EDC, bisphenol A (BPA), has been 
shown to alter embryonic pituitary development in a sex specific manner, however, the 
effects of exposure in the neonatal period have not been examined. Before examining 
the potential sex specific effects of BPA exposure, we first analyzed what baseline sex 
differences exist in the neonatal pituitary. We found that three genes, Lhb, Fshb, and 
Icam5, were higher in females than males and that these genes were decreased by 
exposure to estradiol. All the sexually dichotomous genes were found in the 
gonadotrope cells of the pituitary, demonstrating that even at an early age, there are 
sex differences in the neonatal hypothalamic pituitary gonadal axis and estradiol can 
regulate these differences. Because the neonatal pituitary could be altered by the 
naturally circulating hormonal milieu, we hypothesized that the neonatal pituitary would 
be sensitive to exogenous BPA and estradiol (E2) exposure and there would be sex 
specific effects of this exposure. 
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We examined the effects of exposure to BPA on the neonatal pituitary. 
Interestingly, BPA was able to alter gene expression in the neonatal pituitary, however, 
not in the same way it was able to affect the embryonic pituitary. Proliferation and the 
gonadotrope lineage were altered with embryonic exposure, whereas the 
corticotrope/melanotrope and PIT1 lineages were altered in the neonatal exposure 
paradigm. This suggests that there are differences between the embryonic and neonatal 
period, which may contribute to divergent effects of BPA during the two critical windows 
of development. Additionally, dose and sex specific effects were observed, which shows 
there may be additional sex differences in the neonatal pituitary. This also shows that 
BPA can alter every axis of the pituitary, though the time, dose, and sex are all 
contributing factors to what is altered. 
Due to the ability of E2 and BPA to disrupt estrogen signaling and to regulate 
gene transcription in the pituitary, we examined further the mechanisms by which this 
regulation takes place. We hypothesized that E2 and BPA would be able to regulate 
gene transcription directly at the pituitary and this regulation would be carried out by the 
most ubiquitously expressed estrogen receptor, ESR1. To test this hypothesis, we 
treated pituitaries in ex vivo cultures with E2, BPA, or ER-subtype selective agonists 
and antagonist and analyzed expression of the sexually dichotomous genes. 
Interestingly, sex specific effects were seen with direct stimulation of the pituitary, 
showing that the pituitary itself maintains sex differences. Also, regulation of the 
sexually dichotomous genes in vivo did not always match what was seen in the cultures 
demonstrating other factors may be important in gene regulation. Interestingly, all of the 
sexually dichotomous genes appeared to be regulated via different estrogen receptor-
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subtypes or combinations of subtypes, demonstrating the diversity of estrogen signaling 
pathways within a cell. Of particular interest, Icam5 was regulated by a combination of 
nuclear and membrane signaling demonstrating that this decrease may be through a 
multi-step process that will be analyzed further in the future. Taken together, these 
studies demonstrate that the neonatal pituitary is sensitive to estrogen signaling through 
multiple pathways and therefore, exposure to EDCs that can interfere with this process 
to disrupt the neonatal pituitary in sex specific ways. 
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Chapter 1: Introduction 
Exposure to endocrine disrupting chemicals (EDCs) has increased greatly over 
the past several decades, co-related to an increase in endocrine related health 
concerns, such as infertility, diabetes, thyroid dysfunction, neurological disorders, and 
cancer to name a few. Many of these disorders are more likely to occur if exposure to 
the compound occurs during developmental windows as these periods can be more 
sensitive and disruptions in development and can lead to permanent effects later in life 
(Hanson & Gluckman 2008). Though many outcomes of EDC exposures are known, the 
precise location of the disruption is not well known. Disruption of the pituitary gland 
could potentially be responsible or contribute to development of diseases caused by 
EDCs due to its ability to control several endocrine systems. 
The pituitary is the central gland of the endocrine axes, important in releasing 
hormones that affect growth, metabolism, stress, lactation, and reproduction. In order 
for the pituitary to properly regulate these endocrine axes, it must develop the hormone 
secreting cell types in the right number and proportion. Too many or too few hormone 
secreting cell types can disrupt the amount of hormone released from those cells, which 
can subsequently lead to several endocrine disorders such as gigantism, dwarfism, 
hypothyroidism, hyperthyroidism, Cushing’s syndrome, hyperprolactinemia, and 
hypogonadotropic hypogonadism. Many of these disorders arise while the pituitary is 
developing. Therefore, it is important to understand what controls proper development 
of the pituitary cell types and how exposure to exogenous endocrine disrupting 
chemicals can influence proper development of the pituitary during critical windows. 
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The murine pituitary gland consists of three lobes. The posterior lobe (PL) is 
connected to the hypothalamus via the infundibulum through which the magnocellular 
neurons of hypothalamus travel and release anti-diuretic hormone (ADH) and oxytocin 
(OT) (Markakis 2002). The anterior lobe (AL) consists of the somatotropes, thyrotropes, 
lactotropes, corticotropes, and gonadotropes, which secrete growth hormone (GH), 
thyroid stimulating hormone (TSH), prolactin (PRL), adreno-corticotropic hormone 
(ACTH), and luteinizing hormone (LH) and follicle stimulating hormone (FSH), 
respectively. The intermediate lobe (IL) separates the posterior and anterior lobes and, 
in rodents, it consists of melanotrope cells that secrete melanotropin stimulating 
hormone (MSH). Development of these lobes and cell types within the lobes is a very 
well controlled process from the beginning of organogenesis to maintenance of all the 
cell populations in the adult pituitary. The posterior and anterior lobes of the pituitary are 
derived from different tissues, the neural ectoderm and oral ectoderm, respectively.  
Embryonic pituitary development 
The pituitary develops during two critical windows: embryonic and neonatal. 
During these two periods, different factors are involved in controlling proliferation and 
cell fate choices. Organogenesis of the pituitary begins around embryonic (e) day 8.5 in 
the murine pituitary. At this time the oral ectoderm begins to thicken and invaginate to 
become the beginnings of Rathke’s pouch (Treier et al. 1998). Eventually, Rathke’s 
pouch breaks apart from the oral ectoderm and the pouch becomes an isolated anterior 
pituitary gland containing organ restricted progenitor cells (Bancalari et al. 2012). All the 
hormone-secreting cells of the pituitary are derived from the common progenitor cell 
pool. These cells are generally found lining the cleft between the anterior and 
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intermediate lobes as well as scattered throughout the parenchyma of the anterior lobe 
(Vankelecom 2010). They also express several stem cell markers such as SRY (sex 
determining region Y)-box 2 (SOX2), octamer-binding transcription factor 4 (OCT4), and 
glial cell line-derived neurotrophic factor (GDNF) receptor alpha 2 (GFRa2) (Alatzoglou 
et al. 2009; Garcia-Lavandeira et al. 2009). These progenitor cells give rise to transit 
amplifying cells, which are undifferentiated cells that rapidly proliferate and eventually 
differentiate. Progenitor cells must balance self-renewal, to maintain adequate 
progenitor number in order to expand the size of the pituitary, and differentiation, to 
create all the hormone cell populations in the right proportions for proper functioning of 
the pituitary. Once the transit amplifying cell receives signals to differentiate, it will do so 
to one of the three lineages that make up the pituitary: the SF1, PIT1, and TPIT 
lineages. These lineages are named as such because of the transcription factor 
specifically expressed in these cells that is known to drive the differentiation of the 
specific cell type. The SF1 lineage is characterized by expression of steroidogenic 
factor 1 (SF1). SF1 is the transcription factor important in expression of genes in 
gonadotrope cells. SF1 deficient mice do not produce gonadotropins, suggesting SF1 is 
important in terminal differentiation of these cells. (Ingraham et al. 1994; Zhao et al. 
2001). The PIT1 lineage is characterized by expression of POU domain, class 1, 
transcription factor 1 (PIT1). PIT1, or POU1F1, is a transcription factor found exclusively 
in the pituitary gland and is important in the development of lactotropes, somatotropes, 
and thyrotropes and expression of their respective hormones, as loss of Pit1 results in 
decreased Prl, Gh, and Tshb mRNA as well as severe reduction of the respective cell 
types (Li et al. 1990). The TPIT lineage is characterized by expression of T-box 
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transcription factor (TPIT), also known as TBX19. TPIT is a transcription factor present 
in melanotrope (IL) and corticotrope (AL) cells and is important for terminal 
differentiation of these cells (Pulichino et al. 2003). Absence of TPIT does not lead to 
complete absence of corticotropes, but expression of POMC is delayed and reduced if 
TPIT is absent (Lamolet et al. 2004; Pulichino et al. 2004). Differentiation of the 
hormone secreting cells just described begins around embryonic day (e) 11.5 to 13.5 
(Davis et al. 2011; Seuntjens & Denef 1999) as progenitor cells stop proliferating and 
exit the cell cycle before differentiating. Though all the cell types begin developing at the 
same time, they reach terminal differentiation, marked by expression of hormone, at 
different times. The corticotrope cells are the first to reach terminal differentiation at 
e12.5 followed by melanotrope and thyrotrope cells at e14.5, somatotrope and 
lactotrope cells at e15.5, and finally, the gonadotrope cells at e16.5 in mice (Japon et al. 
1994). A major question of importance in understanding pituitary development is: what 
signals are the pituitary progenitor cells receiving that will cause them to proliferate and 
become fated to a specific lineage? 
Signals: Critical Embryonic Period 
Factors controlling cell expansion and fate choices in the pituitary during the 
embryonic period mainly occur from intrinsic signals. Many studies have been done to 
explore these intrinsic factors involved in proliferation and differentiation in the 
developing pituitary. Proper development of Rathke’s pouch is controlled by a number 
of factors from the surrounding ventral diencephalon. The ventral diencephalon secretes 
bone morphogenetic proteins (BMPs) and fibroblast growth factors (FGFs) that regulate 
the size of the developing Rathke’s pouch (Davis et al., 2013). BMP is necessary for 
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initiation of Rathke’s pouch, as loss of BMP4 leads to a loss of Rathke’s pouch (Treier 
et al. 1998). FGFs are important in cell proliferation, as loss of several FGFs result in a 
hypoplastic Rathke’s pouch and increased apoptosis (Takuma et al. 1998; De 
Moerlooze et al. 2000; Ohuchi et al. 2000). Other signaling pathways can also interact 
with these pathways to affect development of Rathke’s pouch. The WNT and sonic 
hedgehog (SHH) signaling pathways are active in the developing diencephalon and 
pituitary and can influence pituitary growth and differentiation (Cha et al. 2004; Potok et 
al. 2008; Olson et al. 2006; Treier et al. 2001; Wang et al. 2010; Treier et al. 1998). 
Loss of Pitx2, which is induced by WNT signaling, leads to a hypoplastic pituitary 
(Kioussi et al. 2002) and similarly loss of Wnt4 also results in hypoplasia, suggesting 
WNT signaling has a role in progenitor proliferation (Treier et al. 1998). Conversely, 
increased WNT signaling by a degradation resistant form of β-catenin leads to pituitary 
hyperplasia only when targeted to progenitor cells (Gaston-Massuet et al. 2011), 
demonstrating that WNT signaling specifically in progenitor cells leads to pituitary 
proliferation.  
Notch signaling is important in progenitor proliferation and maintenance as loss 
of down-stream target Hes1 causes global reduction of proliferation in the embryonic 
pituitary and loss of RBP-J, the major mediator of Notch signaling, which leads to 
premature lineage differentiation (Raetzman et al. 2007; Zhu et al. 2006). This 
hypoplasia caused by loss of Notch signaling is thus caused by accelerated 
differentiation of progenitor cells (Kita et al. 2007). These signaling pathways also play 
roles in driving progenitor cells within the developing pituitary to adopt certain lineages. 
BMP signaling is important in PIT1 cell specification as reduced BMP signaling causes 
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a loss in the PIT1 lineage (somatrope, lactotropes, and thyrotropes) (Treier et al. 1998). 
WNT signaling may also play a role, as loss of β-catenin leads to loss/reduction of all 
cell types except corticotropes (Olson et al. 2006). SHH signaling can alter cell 
specification, increasing thyrotropes and gonadotropes (Treier et al. 2001). Finally, 
Notch signaling is important in cell specification as loss of Notch-induced transcription 
factor (Hes1) causes cells to switch from melanotropes to somatotropes (Raetzman et 
al. 2007) and loss of a Notch mediator (Rbpjκ) promotes differentiation of corticotropes 
and loss of the PIT1 lineage (Zhu et al. 2006). In sum, the developmental pathways, 
BMP, WNT, SHH, and Notch, are all important in proliferation and cell specification. 
However, with interacting pathways and redundancy, it is still unclear exactly what 
factors specify a cell to adopt a certain lineage and future studies are needed to 
elucidate the roles of each of these pathways. 
Signals: Critical Neonatal Period 
In rodents, there is a second critical period of development, which occurs right 
after birth and lasts for a period of 21 days, however much proliferation and 
differentiation occurs during the first week after birth and tapers off with time (Gremeaux 
et al. 2012). This rodent neonatal developmental period corresponds to the third 
trimester in humans (Anderson et al. 2003), meaning that neonatal pituitary 
development in rodents is still embryonic development in humans. During this neonatal 
period, there are still a vast amount of proliferating progenitor cells (Gremeaux et al. 
2012). There is also a large expansion of the hormone producing cell types (Carbajo-
Perez & Watanabe 1990; Yoshimura et al. 1970; Taniguchi et al. 2002; Taniguchi et al. 
2001). The intrinsic pathways controlling development during the embryonic period are 
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still at play during the neonatal period. An important factor for postnatal pituitary 
proliferation is cyclin-dependent kinase 4 (CDK4). Cdk4 deficient mice have hypoplastic 
pituitaries, which is only apparent postnatally as pituitaries display normal proliferation 
embryonically (Garcia-Lavandeira et al. 2009). Notch signaling, such as through 
NOTCH2, is important for maintaining progenitor cells and proliferation neonatally 
(Nantie et al. 2014). It is also important in postnatal differentiation as loss of Notch2 
decreases PIT1 cell number and increases POMC cell number (Nantie et al. 2014). 
However, less is known about the intrinsic signals regulating postnatal pituitary 
proliferation and differentiation so more studies are necessary. To compound this lack 
of knowledge of factors controlling postnatal development, there is also the increasing 
evidence for extrinsic factors, such as neuroendocrine or endocrine hormones, to 
influence pituitary proliferation and hormone producing cell number. These factors are 
less well studied than the influence of intrinsic signals.  
The potential for hormones to have a greater influence on neonatal pituitary 
development is supported by the development of functional axes, which mainly occurs 
in the late embryonic to neonatal period. The hypothalamic-pituitary-gonadal (HPG) axis 
begins developing before birth as kisspeptin neurons start to communicate with 
gonadotropin releasing hormone (GnRH) neurons. Kisspeptin neurons are present and 
kisspeptin receptor, GPR54, expression in GnRH neurons begins around e13.5 (Kumar 
et al. 2014; Kumar et al. 2015). GnRH neurons reach the median eminence by e16, in 
mice (Schwanzel-Fukuda & Pfaff 1989) and pituitaries can respond to GnRH with 
increased LH, in vitro, at e18 (Pointis & Mahoudeau 1976). Furthermore, in vivo there 
are differences in serum LH levels between males and females corresponding with 
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differences in testosterone as early as postnatal day (PND)1, suggesting functional 
negative feedback of testosterone (Pointis et al. 1980; Poling & Kauffman 2012). More 
evidence that the HPG axis is established embryonically is that GPR54 KO (Kiss1r KO) 
mice have lower gonadotropin serum levels at birth, suggesting the importance of 
kisspeptin signaling. Additionally, hypogonadal (hpg) mice, which lack GnRH, similarly 
demonstrate reduced serum gonadotropin levels at birth (Poling & Kauffman 2012). 
Therefore, it seems evident that the HPG axis is functional in the late embryonic period 
and proper development is identifiable even early in the neonatal period.  
Dopaminergic neurons, important in regulation of prolactin, reach the median 
eminence around e19-20, in rats (Szabat et al. 1998). In vitro, a dopamine receptor 
agonist can inhibit PRL secretion as early as e19 and co-culture of hypothalamic 
extracts of day old rats with pituitaries of the same age stimulated PRL release 
(Khorram et al. 1984), showing that the axis is at least partially developed. However, in 
vivo, PRL secretion is low embryonically and neonatally (Dohler & Wuttke 1975). This 
could be due to low levels of estrogens (Dohler & Wuttke 1975) and the ability of alpha 
fetoprotein to bind estrogens (Terentiev & Moldogazieva 2013) thus preventing 
stimulation of Prl transcription and secretion by estrogens. There are also higher levels 
of glucocorticoids in the late gestational period, which peaks at e16-17 in the mouse. 
Glucocorticoids have been shown to inhibit Prl gene expression (Somasekhar & Gorski 
1988) though the mechanism by which this happens is unclear (Ogasawara et al. 2009). 
Therefore, the ability for prolactin to be hormonally regulated is also somewhat 
developed embryonically.  
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The growth hormone (GH) axis is still developing during the neonatal period as 
well. In rats, GH secretion, in vitro, cannot be induced until e21 (one day before birth) 
(Khorram et al. 1983) and cannot be inhibited by somatostatin until postnatal day (PND) 
3-5 in rats, in vivo and in vitro (Rieutort 1981; Khorram et al. 1983) indicating that the 
growth axis is still very much under development during the late embryonic and 
neonatal period. Proper functioning of the growth hormone axis may also play a role in 
pituitary development. Little mice, which lack the growth hormone releasing hormone 
(GHRH) receptor (GHRHR) develop normally in the embryonic period, but there is 
hypoplasia due to failure of somatotrope expansion in the mature pituitary (Lin et al. 
1993). This suggests that GHRH is important for maintenance and expansion of 
somatotrope cells in the neonatal period.  
In regards to the hypothalamic-pituitary-thyroid (HPT) axis, thyrotropin releasing 
hormone (TRH) is detected in the hypothalamus as early as e12 in the rat (Nemeskeri 
et al. 1985). However, the neonatal rat still has low levels of thyroid hormone (T4) at 
birth, which increase around PND4 (Dussault & Labrie 1975). The HPT axis does not 
fully mature until around PND7 in the rat (Taylor et al. 1990).  However, exogenous 
TRH during the neonatal period still elicits an increase in TSH (Bakke et al. 1974), 
suggesting that the axis can be activated. Furthermore, it seems that despite the axis 
not being fully developed, hypothyroidism can cause elevated serum TSH at birth, 
suggesting feedback of thyroid hormones on the pituitary can occur in the fetus (Oliver 
et al. 1980).  
Finally, with the hypothalamic-pituitary-adrenal (HPA) axis, corticotropin releasing 
hormone (CRH) is detectible in the hypothalamus around e17 in the rat (Baram & 
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Lerner 1991). ACTH and corticosterone are detectible in the fetal plasma on e16 in rats 
(Boudouresque et al. 1988). In rats, the HPA axis becomes responsive to changes in 
corticosteroids around e18, as evidenced by changes in adrenal weight of the fetus 
(Milkovic et al. 1973). These data point to the possibility of the HPA axis being 
functional prior to birth. However, during the neonatal period there is a hypo-responsive 
period in which mild stressors cannot induce enhanced ACTH and corticosterone levels 
(Schmidt et al. 2003). However, some studies have suggested that this is not a hypo-
responsive period, but rather a delayed responsive period. PND2 neonatal rats exposed 
to stress still exhibit increased CRH and glucocorticoids, albeit about 40 minutes after 
these same factors would increase in an adult (Hiroshige et al. 1971). Therefore, all the 
functional axes involving the pituitary appear to be developing during this late embryonic 
and neonatal time. Knowledge that the axes are functional or developing during this 
neonatal period suggests that these endocrine and neuroendocrine hormones can 
potentially regulate pituitary development. These endocrine signals could influence cell 
population size and play a vital role in fine tuning or maturation of the cell types. 
Role of Estrogens in Pituitary Development 
One hormone that has been demonstrated to have a profound developmental 
role is estradiol (E2). E2 in embryonic and neonatal female rat circulation is estimated to 
be 2-10 pg/ml, values similar to free estradiol in adult female rats in proestrus, and are 
not different between males and females (Montano et al. 1995; Konkle & McCarthy 
2011). E2 levels are highest at birth (50 pg/ml) in both males and females (Konkle & 
McCarthy 2011). However, high levels of alpha-fetoprotein during development bind 
estrogens, keeping most of them from being active. Importantly, local conversion of 
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estradiol from testosterone via aromatase is the main source of developmental estrogen 
exposure and this plays a major role in the establishment of sex differences during the 
late embryonic and neonatal period (McCarthy 2008; Simerly 2002; Simerly et al. 1985; 
Simerly 1989; Clarkson et al. 2014). In mice, males have higher levels of testosterone 
beginning around e13, which is followed by a testosterone surge at birth (Clarkson & 
Herbison 2016). Serum testosterone levels are higher in males than females 4 hours 
after birth, but there is no longer a difference in testosterone levels between males and 
females after 16 hours in mice (Poling & Kauffman 2012), showing that the testosterone 
surge only lasts for a brief period of time, despite its extreme importance in 
establishment of sex differences. Levels of testosterone are similar between males and 
females until PND10 when testosterone levels are once again higher in males than 
females (Poling & Kauffman 2012).   
There is a potential for aromatase expressed in the pituitary to play an important 
role as well. Studies have shown that both E2 and testosterone suppress Lhb mRNA 
and LH serum levels, however, this was not seen with either treatment in Esr1 knockout 
mice, suggesting androgens must be converted to E2 (Lindzey et al. 1998). Aromatase 
is higher in males than females in the adult and is expressed in gonadotropes, 
somatotropes, lactotropes, and thyrotropes (Carretero et al. 1999; Galmiche et al. 2006; 
Caglar et al. 2015). It is clear that sex steroids create differences in the male and female 
brain. However, it has not been shown whether these same perinatal hormones create 
sex differences at the level of the pituitary.  
The effect of estrogens in pituitary development are not yet clear.  Estrogens 
have been demonstrated as potent mitogens in a number of tissues including the 
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uterus, mammary gland, adrenal gland, and pituitary (Cunha & Lung 1979; Anderson et 
al. 1998; Bayne et al. 2008; Sabatino et al. 2015). In the pituitary, long-term estradiol 
administration drives the creation of prolactin secreting tumors or prolactinomas 
(Takekoshi et al. 2014). Estrogens act by increasing production of growth factors, such 
as transforming growth factor (TGF)β, that will induce proliferation and differentiation. 
Induction of galanin, a lactotrope growth factor, is thought to mediate the stimulatory 
effects of estradiol on lactotrope proliferation as galanin anti serum prevents the actions 
of estradiol on lactotrope cells (Wynick et al. 1993; Denef 2003). It is clear that estrogen 
exposure can promote lactotrope proliferation in the adult, but it is not clear if the same 
thing happens in the developing pituitary or if estrogen exposure can fate cells to 
become lactotropes. Few lactotrope cells are identifiable embryonically, however, 
treatment with estradiol or diethylstilbestrol (DES) can increase the number of PRL 
positive cells (Ogasawara et al. 2009; Matsubara et al. 2001). However, it has been 
shown that estradiol induces prolactin production in development similarly to the adult 
(Ogasawara et al. 2009; Kiino & Dannies 1981); therefore, it is possible that estradiol is 
not necessarily increasing lactotrope cell number, but is advancing onset of PRL 
expression in already present lactotrope cells, thus advancing terminal differentiation. 
Furthermore, the role of naturally circulating estradiol during this time may be minimal 
because the minimum dose needed to induce lactotropes to initiate PRL production is 
10 pM in mice at e15 (Ogasawara et al. 2009), which is below the amount of free 
estradiol in circulation during this time, 0.5-2.2pg/ml (Montano et al. 1995). Furthermore, 
estrogen receptor alpha knockout (ESR1 KO) mice still have lactotrope cells, 
suggesting again that estrogen is not required for differentiation of these cells. There 
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are fewer lactotrope cell numbers in the adult ESR1 knockout mice compared to control, 
however, demonstrating the importance of estrogens in lactotrope cell growth 
(Ogasawara et al. 2009; Scully et al. 1997). 
In the embryonic pituitary, estradiol exposure increases proliferation and 
gonadotrope cell number in chick embryos (Wu et al. 2009). During the embryonic 
period, the main cells that are proliferating are progenitor and transit amplifying cells, 
which then differentiate to hormone producing cells. It is possible that E2 exposure 
causes an increase in progenitor proliferation and subsequent differentiation to the 
gonadotrope lineage. Estrogens may increase progenitor proliferation indirectly as 
pituitaries treated in vivo with estradiol demonstrate an increase in progenitor 
proliferation, however, isolated progenitor cells treated with estradiol in vitro do not 
(Rizzoti et al. 2013), showing that some kind of indirect cell signaling has to take place 
to increase progenitor proliferation. Interestingly, exposure to the estrogen receptor 
modulator, tamoxifen, also causes an increase in cells adopting the gonadotrope 
lineage during the neonatal period (Rizzoti et al. 2013). However, other studies have 
demonstrated conflicting results as treatment with DES to neonatal pituitaries in culture 
did not alter LH cell number, despite being able to alter expression of estrogen 
regulated genes (Ishikawa et al. 2014). Despite the apparent ability of estrogens to 
advance gonadotrope cell number, ESR1 KO mice still have gonadotrope cells. 
However, there does appear to be a difference in the morphology of these cells, as the 
adult ESR1 KO mice have less homogenous gonadotropes than control mice. Estradiol 
increases the percentage of homogenous gonadotropes in both control and ESR1 KO, 
suggesting a role of ESR2 in this process (Sanchez-Criado et al. 2012). Given these 
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data, it is possible that estrogen signaling can modulate progenitor proliferation and 
differentiated cell number, but likely is not necessary for initial gonadotrope or lactotrope 
specification. 
Endocrine Disruption by Bisphenol A 
The ability of estrogens to alter proliferation and cell fate choices in the 
developing pituitary as well as generate sex differences opens up the possibility of the 
pituitary to be similarly affected by exposure to endocrine disrupting chemicals (EDCs). 
One such compound is bisphenol A (BPA).  BPA is a plasticizer found in polycarbonate 
plastics, epoxy resins, and thermal paper (Shelby 2008). BPA was developed in the 
1890s and was first reported to have estrogenic properties in the 1930s (Dodds & 
Lawson 1936). Despite a low binding affinity to the classical estrogen receptors ESR1 
and ESR2, which is about 10,000 fold weaker than estradiol (Kuiper et al. 1998), BPA 
has still been shown to have effects similar to estradiol. BPA can also bind the 
membrane estrogen receptor, GPER, with an affinity that is 8-50 times higher than the 
affinity for the ERs (Thomas & Dong 2006). Therefore, many studies have focused on 
comparing the effects of BPA to that of estradiol.  
Very few studies have looked at the effects of BPA on the pituitary and fewer still 
have looked at the effects on the developing pituitary. A previous study in our lab shows 
that embryonic exposure to environmentally relevant doses of BPA increases pituitary 
proliferation and gonadotrope cell number in female offspring, but not male offspring 
(Brannick et al. 2012). This increase in proliferation and gonadotrope number is 
consistent with effects of estrogen as discussed previously. A similar increase in 
pituitary proliferation is seen with BPA exposure in the adult rat through placement of 
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dental fillings, another common source of BPA exposure. Although a precise dose was 
not determined in this study, it is assumed to be low as BPA would be eluted during 
mastication over a long period of time. Along with the increase in proliferation there was 
also an increase in lactotrope cell number (Velasco-Marinero et al. 2011), again 
consistent with expected results of estrogenic exposure as discussed previously. BPA is 
also able to induce proliferation and prolactin protein synthesis in a prolactin secreting 
pituitary cell line, PR1. The ability of BPA to induce proliferation in these cells is about 
10,000 fold less than E2, however, it is blocked by the antiestrogen, ICI 182,780, 
suggesting that BPA affects proliferation through the ER (Chun & Gorski 2000). These 
studies suggest the possibility for BPA to alter pituitary proliferation and cell fate 
choices. However, these few studies did not fully determine the effects on the pituitary 
during other developmental periods, such as the neonatal period, and therefore more 
studies are warranted.  
Despite the lack of studies specifically examining the effects of BPA on pituitary 
development there are a number of studies that examine the effects of developmental 
exposure to BPA on hormonal factors related to the pituitary. One of the best studied 
axes in relation to the effects of BPA is the hypothalamic-pituitary-adrenal (HPA) axis. In 
the HPA axis, corticotropin releasing hormone (CRH) from the hypothalamus binds the 
CRH-receptor (CRHR1) on the corticotrope cells of the anterior pituitary, which leads to 
the release of adrenocorticotropic hormone (ACTH).  ACTH then causes the release of 
glucocorticoids from the adrenal gland, which will provide negative feedback on the 
hypothalamus and pituitary. Sex steroids have a critical role in development of sex 
differences in this axis basally and after stress. Males have higher CRH and lower 
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glucocorticoid receptor (GR) and neonatal estrogen makes females more male-like 
(Patchev et al. 1995).  
Exogenous exposure to estrogens can influence proper functioning of the HPA 
axis. DES exposure in pregnant women increases depression and anxiety in their 
offspring (Vessey et al. 1983). Estrogen exposure also alters normal anxiety related 
behavior during neonatal development (Leret et al. 1994). Similarly, exposure to BPA 
can influence proper development of the HPA axis. Developmental BPA exposure 
(40μg/kg/day, which is a dose similar to dose that increased pituitary proliferation and 
gonadotrope number (Brannick et al. 2012)) increases anxiety-like behavior and 
hyperactivity of the HPA axis via impaired glucocorticoid negative feedback (Zhou et al. 
2015). Embryonic and lactational exposure to 2 μg/kg/day BPA similarly increases 
anxiety and depression behaviors. This dose also demonstrates HPA axis activation, 
including increased Crh mRNA and increased serum ACTH and corticosterone levels in 
males at PND80. BPA also decreases Nr3c1 mRNA, which is the gene for the 
glucocorticoid receptor, GR, suggesting that hyperactivation of the HPA axis may be 
due to decreased negative feedback (Chen et al. 2015). In a parallel study, females did 
not have changes in Crh mRNA or serum ACTH and corticosterone. However, BPA 
treated females did have reduced response to stress, meaning lower elevation in 
corticosterone, with BPA treatment. Males had increased response to stress, meaning 
higher elevation in corticosterone. This difference could be because Nr3c1 mRNA is 
increased in females, whereas it is decreased in males with BPA exposure (F. Chen et 
al. 2014). However, in another study using 40 μg/kg/day BPA exposure during 
pregnancy and lactation, BPA increased serum corticosterone and decreased GR 
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protein levels in females, but not males. Interestingly, stress increased Crhr1 and Pomc 
mRNA levels in BPA treated males, but not females in PND46 rats (Panagiotidou et al. 
2014), which again suggests hyper-activation of the HPA axis in males with stress and 
basal hyper-activation of the HPA axis in females. The differences between effects of 
studies could be due to dose used or the age examined. However, many of these 
studies showed that BPA decreased GR, which would be the expected effect of 
neonatal estrogenic exposure (Patchev et al. 1995). Overall, these studies indicated 
that BPA can alter HPA axis function, alter basal sex differences, and have sex specific 
effects. 
Another axis that is profoundly affected by BPA exposure is the hypothalamic-
pituitary-gonadal (HPG) axis. In the HPG axis, gonadotropin releasing hormone (GnRH) 
is released from GnRH neurons. GnRH then binds to GnRH receptors on the 
gonadotrope cells in the anterior pituitary and stimulates the release of luteinizing 
hormone (LH) and follicle stimulating hormone (FSH). These hormones travel to the 
gonads and stimulate the production of sex steroids, estrogen and testosterone, which 
generally provide negative feedback on the hypothalamus and pituitary. Developmental 
exposure (embryonic and lactational) to rodents of environmentally relevant (0-50 
mg/kg/day) (Vandenberg et al. 2012) doses of BPA lead to altered serum levels of 
hormones in rodents. Gestational and lactational exposure to approximately 3 μg/kg/day 
leads to increased LH and estradiol serum levels in females (only females were 
analyzed), but FSH is unaffected at PND30 (Gamez et al. 2015). Males treated 
embryonically with 2.5 and 25 μg/kg/day BPA show a similar increase in LH protein at 
PND35, but then a decrease in LH and FSH at PND90 (Abdel-Maksoud et al. 2015). 
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Along with this, embryonic exposure to 0.5 μg/kg/day BPA increases Lhb mRNA, 
whereas 50 μg/kg/day BPA decreases Lhb mRNA in female offspring at PND0 
(Brannick et al. 2012). Slightly higher doses of 12-50 mg/kg/day BPA, but still below the 
LOAEL of 50 mg/kg/day, from gestation to five weeks of age does not affect Lhb, Tshb, 
Gh, or Prl mRNA levels in males or females, but does increase Fshb in females at 25 
and 50 mg/kg/day and males at 25 mg/kg/day (Xi et al. 2011). Neonatal exposure to 
2.5-6.2 mg/kg/day BPA or 25-62.5 mg/kg/day BPA decreased the GnRH stimulated 
release of LH and disrupted GnRH pulsatility at PND13 (Fernandez et al. 2009). 
However, another study determined that neonatal exposure to BPA at 50 μg/kg/day and 
50 mg/kg/day, which is sufficient to disrupt reproductive development, does not alter the 
ability of GnRH to respond to steroid feedback (Adewale et al. 2009). From these 
studies, it seems clear that BPA is able to disrupt development of the HPG axis.  
Similar to the HPA axis, the HPG axis exhibits sex differences that are 
established by the neonatal testosterone surge, and like the HPA axis, BPA is able to 
alter expression of sex specific genes and characteristics in the HPG axis. Embryonic 
and lactational dosing of 25 or 250 ng/kg BPA decreases and eliminates the sex 
difference in tyrosine hydroxylase expression in the anteroventral periventricular 
nucleus (AVPV) (Rubin et al. 2006). The AVPV houses the kisspeptin neurons 
important in the generation of the LH surge that occurs in females. Females have a 
larger population of kisspeptin neurons and therefore have a larger amount of tyrosine 
hydroxylase (TH) expression than males. The neonatal testosterone surge is 
responsible for generating this sex difference as higher amounts of testosterone, which 
is converted to estrogen, decreases kisspeptin neuron numbers in the AVPV. 
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Interestingly, if females are treated with estradiol during the neonatal period, their AVPV 
will be smaller and more similar to a male. (Simerly 1989; Kelly et al. 2013). However, 
another study showed that exposure to 250 μg BPA from PND1-2 actually increased TH 
cells in the male AVPV to make it more like a female (Patisaul et al. 2006), 
demonstrating an anti-estrogenic effect. Exposure to 50 μg or 50 mg of BPA from 
PND0-2 showed sex specific effects of BPA on Esr1, (gene for ESR1), Esr2 (gene for 
ESR2), and Kiss1 mRNA expression, however in this study BPA did not simply mimic 
actions of estrogen, suggesting the ability to alter hypothalamic organization via other 
pathways (Cao et al. 2012).  
Few studies have examined possible sex difference in the pituitary with regards 
to the HPG axis. In fact, our lab’s previous study is the only one, which showed that only 
female offspring were affected by embryonic exposure to BPA (Brannick et al. 2012). 
The reasons why BPA would have sex specific effects are unknown, however, it is likely 
due to its action as a sex steroid mimic or inhibitor. It could also be due to differences in 
innate expression of genes and receptors that allow BPA to have an effect in one sex, 
but not the other. More studies are needed in order to determine what sex differences 
exist so it can be determined how BPA can potentially modulate them.  
Exposure to BPA is generally considered to be oral for terrestrial animals as BPA 
leaches from food and drink containers (Lakind & Naiman 2008). In order to understand 
how method of exposure to BPA could affect the results, it is important to understand 
how BPA is processed in the body. Normally when BPA is ingested it will go through 
first pass metabolism in the liver and gut and become converted to the inactive BPA 
glucuronide (Matthews et al. 2001) by uridine diphosphate glucuronosyltransferases 
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(UGTs). It will then be cleared via urine in humans (Volkel et al. 2002) and mainly in 
feces in rodents (Zalko et al. 2003). Activity of UGTs is lower embryonically and 
increases with age, not reaching the level of activity seen in the adult until PND21. This 
potentially prolongs the elimination half time in embryonic and neonatal mice compared 
to the adult (Doerge et al. 2011). During embryonic development, dams are orally dosed 
with BPA, this BPA then goes through first pass metabolism in the mom before reaching 
the fetus. Concentrations of BPA in maternal blood and tissue parallel that of the fetus 
(Kim et al. 2001; Moors et al. 2006) suggesting that the placenta is not a barrier for BPA 
transfer, thus giving the fetus similar exposure to BPA as the dosed mother. However, 
as the activity of UGTs increases in the fetus with age the amount of active BPA (BPA 
aglycone) decreases. During neonatal development, UGT activity is not yet sufficient to 
cause differences in circulating BPA concentrations until after PND3 due to method of 
exposure. Subcutaneous injections and oral exposure on PND3 cause the same 
circulating concentrations of BPA. However at PND10, subcutaneous injections lead to 
higher concentrations of BPA than oral exposure (Doerge et al. 2011). Lactational 
delivery of BPA is also somewhat controversial as the doses the pups receive are about 
300-500 fold lower than the amount given to the mother (Doerge et al. 2010). Despite 
the limitations of method of exposure, especially during the neonatal period, it is clear 
that effects are still observable with BPA. It is just important to keep in mind that 
subcutaneous injections could lead to stronger effects due to higher circulating levels of 
BPA, whereas lactational exposure may lead to lesser effects due to inability of BPA to 
transfer to milk at the same concentration as the mother was dosed with. 
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Defining critical windows of exposure to endocrine disrupting chemicals is of 
great concern given the rise of EDCs in the environment. These chemicals can 
influence all aspects of the endocrine system including the center of the axes, the 
pituitary. My study examined how BPA will differentially regulate pituitary development 
in the embryonic vs the neonatal period and discovered sex differences that exist in the 
pituitary after exposure to the testosterone surge. We hypothesized that due to potential 
differences in signals modulating pituitary development during the embryonic and 
neonatal periods and differences in the pituitary between these periods that the pituitary 
may be differentially sensitive to BPA exposure during these times. The studies outlined 
here aim to address: 1) determining the gene expression sex differences in the neonatal 
period and whether these differences can be regulated by exposure to estrogen or BPA, 
2) determining the effects of neonatal exposure to estradiol and BPA on pituitary 
development, 3) uncover the mechanism by which estrogens regulate expression of 
differentially expressed genes in the pituitary. 
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Chapter 2:  Icam5 expression exhibits sex differences in the neonatal pituitary 
and is regulated by estradiol and bisphenol A 
 
Published: Eckstrum, K. S., Weis, K. E., Baur, N. G., Yoshihara, Y., Raetzman, L.T. 
(2016). Icam5 expression exhibits sex differences in the neonatal pituitary and is 
regulated by estradiol and bisphenol A. Endocrinology, 157(4), 1408-1420.   
 
Abstract 
Endocrine disrupting chemicals (EDCs) are prevalent in the environment and can 
impair reproductive success by affecting the hypothalamic-pituitary-gonadal (HPG) axis. 
The developing pituitary gland is sensitive to exposure to EDCs, such as bisphenol A 
(BPA), and sex-specific effects can occur. However, effects on the critical window of 
neonatal pituitary gland development in mice have not been explored. Therefore, this 
study determined baseline gene expression in male and female pituitaries and 
consequences of environmental exposure to 17β-estradiol (E2) and BPA on 
transcription of genes exhibiting sex differences during the neonatal period. Through 
microarray and qRT-PCR analysis of pituitaries at PND1, three genes were differentially 
expressed between males and females: Lhb, Fshb, and intracellular adhesion molecule-
5 (Icam5). To see if E2 and BPA exposure regulates these genes, pituitaries were 
cultured at postnatal day (PND)1 with 10-8M E2 or 4.4x10-6M BPA. E2 decreased 
expression of Lhb, Fshb, and Icam5 mRNA in females, but only significantly decreased 
expression of Icam5 in males. BPA decreased expression of Icam5 similarly to E2, but it 
did not affect Lhb or Fshb. Importantly, in vivo exposure to 50 μg/kg/day E2 from PND0-
7 decreased expression of Lhb, Fshb, and Icam5 mRNA in both males and females 
while 50 mg/kg/day BPA exposure during the same time frame decreased expression of 
Icam5 in females only. Overall, we have uncovered that genes differentially expressed 
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between the sexes can be regulated in part by hormonal and chemical signals in vivo 
and directly at the pituitary and can be regulated in a sex-specific manner. 
Introduction: 
Endocrine disrupting chemicals (EDCs) in the environment are correlated in 
humans with impaired reproductive health including: decreasing age of onset of puberty, 
infertility, miscarriage, and decreased sperm quality (Maffini et al. 2006; Rochester 
2013). These disruptions may originate from alterations in development or function of 
the pituitary, which is a critical component of the hypothalamic-pituitary-gonadal (HPG) 
axis. Exposure to EDCs during developmental windows may be more detrimental as 
these periods can be more sensitive and disruptions in development can lead to 
permanent effects later in life (Hanson & Gluckman 2008). Expansion of the pituitary 
gland occurs embryonically through the first two postnatal weeks in the mouse to create 
the hormone-secreting cell types including somatotropes, lactotropes, gonadotropes, 
corticotropes, thyrotropes, and melanotropes (JACOBSON et al. 1979; Treier & 
Rosenfeld 1996; Carbajo-Perez & Watanabe 1990). The cells subsequently form 
functional networks through cell-cell contact, which is crucial in generating proper 
hormone release (Bonnefont et al. 2005). The neonatal period of development is of 
particular interest because, unlike the embryonic period, the axes connecting the 
hypothalamus, pituitary, and target organs are established allowing for influence of 
circulating hormones. In terms of HPG axis; the pituitary becomes responsive to 
gonadotropin-releasing hormone (GnRH) at e16, when the axons of GnRH neurons 
reach the median eminence, (Wen et al. 2010; Pointis et al. 1980) and the testes can 
secrete testosterone in response to luteinizing hormone (LH) (Pointis et al. 
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1980).Therefore, it is possible that circulating hormones, as well as EDC exposure, 
during the neonatal period could affect development of the pituitary, potentially having 
permanent effects. It is unknown if there would be a difference between males and 
females with respect to pituitary development or response to EDCs during this time.  
One prevalent EDC is bisphenol A (BPA), a plasticizer found in polycarbonate 
plastics, epoxy resins, and thermal paper (Shelby 2008), leading to daily exposure in 
humans. BPA’s mode of action is considered to be estrogenic, despite its binding affinity 
to the classical estrogen receptors (ESR1 and ESR2) being about 10,000 fold weaker 
than that of estradiol (Kuiper et al. 1998). BPA has a better binding affinity to the 
membrane G protein-coupled estrogen receptor, GPER, (Thomas & Dong 2006). The 
pituitary expresses estrogen receptor alpha (ESR1) and estrogen receptor beta (ESR2) 
before birth (Nishihara et al. 2000). GPER is expressed in the adult pituitary as well, 
however expression in the developing pituitary is unknown (Hazell et al. 2009). Since 
the pituitary possesses these estrogen receptors, it is possible that estrogens and BPA 
can affect neonatal pituitary development either directly or indirectly through the 
hypothalamus, which also expresses GPER, ESR1 and ESR2 (Hazell et al. 2009; Mitra 
et al. 2003; Merchenthaler et al. 2004). 
In rodent models, developmental exposure to BPA adversely affects the HPG 
axis. For example, developmental BPA exposure can advance the age of vaginal 
opening and first estrus as well as cause various fertility problems (Maffini et al. 2006; 
Wang et al. 2014; Losa-Ward et al. 2012). These effects have been correlated with 
elevated levels of Kiss1 and Gnrh mRNA in the hypothalamus and Fshb mRNA in the 
pituitary (Xi et al. 2011). Similarly, neonatal exposure to BPA alters estrous cyclicity and 
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impairs LH release (Monje et al. 2010; Fernandez et al. 2009). Thus, developmental 
time periods are sensitive to endocrine disruption, which can have lasting effects on 
function of the HPG axis. Despite the abundance of knowledge regarding the adverse 
effects of BPA exposure on the HPG axis, very few of these studies closely examined 
the pituitary or deciphered if effects seen in vivo occurred at the pituitary itself. 
BPA not only impacts the proper functioning of the HPG axis, but also has a 
number of sex-specific effects. The anteroventral periventricular nucleus, AVPV, is a 
sexually dimorphic nucleus important for generation of the LH surge in females. 
Estrogen, converted from testosterone via aromatase, is responsible for generation of 
the sex differences in the brain (Simerly 2002). Developmental BPA exposure alters the 
size of the AVPV to make males and females more similar (Patisaul et al. 2006; Rubin 
et al. 2006) and alters sex differences in gene expression of Esr1, Esr2, Esrrg, and 
Kiss1 (Cao et al. 2012; Kundakovic et al. 2013). In the pituitary, embryonic exposure to 
BPA leads to an increase in gonadotrope number and altered gonadotrope-specific 
mRNA in females, but not in males (Brannick et al. 2012). However, it is unknown if 
BPA would have a sex-specific effect on the pituitary during the critical neonatal period 
of development.  
To understand why BPA has differing effects in males and females, it is important 
to characterize baseline differences between the sexes. Focusing on the pituitary, only 
43 genes are differentially expressed in adults between males and females (Nishida et 
al. 2005). No studies have been done to determine the sex differences during the 
neonatal period of development. However, it is known that serum levels of gonadotrope-
derived luteinizing hormone (LH) and follicle stimulating hormone (FSH) are higher in 
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females than males at the day of birth (Poling & Kauffman 2012). It is also apparent that 
proper functioning of the HPG axis is essential for manifestation of this sex difference 
because hypogonadal mice (hpg), which lack GnRH signaling, do not exhibit a sexual 
dimorphism in LH and FSH serum levels (Poling & Kauffman 2012). Despite the 
differences in LH and FSH serum levels at birth and apparent dependence on GnRH, it 
is unknown what other differences exist in the pituitary during the neonatal period and if 
there is any direct contribution of sex steroids to pituitary sexual dichotomy. 
We hypothesize that there are sex differences in gene expression at the level of 
the pituitary during the neonatal period and these genes can be regulated by hormones 
and EDCs. To test this hypothesis, we analyzed global mRNA expression in male and 
female CD-1 mouse pituitaries during the neonatal period. We found very few sex 
differences besides Lhb and Fshb during this neonatal period at the mRNA level. One 
novel gene uncovered was intracellular adhesion molecule 5, Icam5. ICAM5 
characteristically is expressed on dendritic filopodia of telencephalic neurons and is 
involved in dendritic shape changes during development (Tian et al. 2007; Tian et al. 
2000; Nyman-Huttunen et al. 2006). In the pituitary, we demonstrated that ICAM5 is 
detected predominantly in gonadotropes. We then showed that, 17β-estradiol (E2) and 
BPA could disrupt gene expression of differentially expressed genes, including ICAM5, 
in the pituitary. These findings indicate the neonatal pituitary is sensitive to exogenous 
EDC exposure. 
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Materials and Methods 
Mice 
CD-1 mice were bred in house. Sex was confirmed by visual inspection and SRY 
genotyping using the primer sequences SRY forward 5’ to 3’ 
TGCAGCTCTACTCCAGTCTTG and reverse 5’ to 3’ GATCTTCATTTTTAGTGTTC (Life 
Technologies).  The University of Illinois Urbana-Champaign Institutional Animal Care 
and Use Committee approved all procedures.  
Microarray: 
Control postnatal day (PND) 1 male and female pituitaries were collected and 
stored in RNAlater (Ambion) at -20°C. Two pituitaries of same sex were then pooled 
and four independent pools were made for each sex. RNA was isolated using the 
RNAqueous-Micro Kit (Ambion). RNA was sent to Roy G. Carver Biotechnology Center 
(University of Illinois at Urbana-Champaign). Agilent Mouse 4 × 44K expression 
microarrays were used to examine pituitary gene expression. Total RNA, (200 ng per 
sample), was reverse transcribed and linear-amplified according to the manufacturer's 
instructions using the Agilent Low Input QuickAmp labeling kit (Agilent Technologies, 
Santa Clara, CA, USA) and labeled with either Cy3 or Cy5 dyes. One of the male 
samples failed to label well so the other sample in the same dye was used twice. 
Samples (two per array) were hybridized on the microarray slide and washed according 
to the Agilent protocol. Slides were scanned using an Axon 4000B scanner, and images 
were analyzed with genepix 6.1 software (Molecular Devices, Sunnyvale, CA, USA).  
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Quantitative RT-PCR 
For sex difference RNA analysis, two litters were combined and analyzed at 
PND0 (n=10-15), PND4 (n=7-11), PND9 (n=10-11), and adult (n=7). One litter was 
analyzed at PND20 (n=6-7). RNA processed as previously described (Nantie et al. 
2014). Gapdh, Lhb, and Fshb primers were used previously in our lab (Brannick et al. 
2012). For Icam5, the sequences used were forward 5’ to 3’: 
CCAAACAGCTGATGTGCGTC and reverse 5’ to 3’: AGAGGAGTCGGGAAGCTGTA. 
For Eif2s3x the sequences used were forward 5’ to 3’: GGGACCAAAGGGAACAAG 
and reverse 5’ to 3’: AGCATCCTAGCCATCAAAATATCA (Life Technologies).  Data 
were analyzed using the standard comparative ΔCT value method as previously 
described (Goldberg et al. 2011). The error bars in the figures represent the SEM of the 
relative fold-change for each group.   
Immunohistochemistry: 
LHβ staining was performed on paraffin sections as previously described 
(Brannick et al. 2012) on PND0 (day of birth). Three slides evenly spaced spanning the 
entire pituitary from four male and female CD1 pups were stained with anti- LHβ 
antibody. The number of LHβ positive cells were counted and divided by the total 
number of cells in the anterior lobe. Sections on a slide, as well as slides per animal, 
were averaged together to obtain the mean % positive LHβ cells. 
For ICAM5 staining, pituitaries from three male and female PND7-PND9 mice were 
fixed in 3.7% paraformaldehyde, cryoprotected in 30% sucrose/PBS solution, then 
frozen in Optimal Cutting Temperature compound (Electron Microscopy Sciences). The 
ICAM5 antibody was applied on 10 μm sections (Yoshihara et al. 1994). For double 
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stains with ICAM5, three female pituitaries were stained at PND9 for LHβ, TSHβ, ACTH, 
and GH and at PND75 for PRL and LHβ.  All antibodies are listed in Table 1. All 
experiments contained a slide without any primary antibodies to ensure specificity. 
Slides were counterstained with 4’,6-diamidino-2-phenylindole (DAPI; 1:1000; Sigma) 
and visualized and processed as previously described (Brannick et al. 2012). 
In situ Hybridization: 
An antisense probe for Icam5 was prepared from mouse cDNA using sequence-
specific primers, forward primer 5’-3’ ATGACTTGGATTGTCCCAGAAG and reverse 
primer 5’-3’ CAGGTTACCAGGGGTCATAGAG. The resulting PCR product was cloned 
into pGEM-T easy vector following the manufacturer’s guidelines (Promega). The probe 
was linearized and transcribed with T7 polymerase (Promega) in the presence of 
digoxigenin-labeled nucleotides (Roche). In situ hybridization was performed on three 
PND9-11 male and female pituitaries prepared as for ICAM5 IHC above. For in situ 
hybridization, pituitaries were thawed and fixed with 3.7% paraformaldehyde, 
permeabilized with proteinase K (0.1μg/ml) (Life Technologies), and incubated with the 
Icam5 probe at 55°C overnight. Probe detection was carried out as previously described 
(Nantie et al. 2014). Slides were then counterstained with methyl green (National 
Diagnostics) and mounted with Permount Mounting Medium (Fisher). 
17β-Estradiol and BPA Culture Experiments 
PND1 pituitaries were cultured overnight on Millicell CM membranes (Millipore) in 
a 24 well plate. The culture media consisted of phenol red-free DMEM/F12 (Fisher), 
supplemented with 10% charcoal-stripped FBS (Sigma) and 100x Penicillin-
streptomycin solution (Fisher). A dose response curve for BPA (Aldrich ≥ 99% purity) 
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was performed including: vehicle control (0.1% ethanol), 4.4x10-8M BPA, 4.4x10-7M 
BPA, 4.4x10-6M BPA, and 4.4x10-5M BPA. Male and female pituitaries were pooled with 
4-5 pituitaries in each group. Assuming that all BPA in an in vivo treatment paradigm 
reaches the pituitary, a dose of the lowest observed adverse effect level (LOAEL) (50 
mg/kg/day) would equate to 50 μg/ml or 2.106x10-4M (Peretz et al. 2012; Peretz et al. 
2011). Therefore, the in vitro dose response corresponds to in vivo doses ranging from 
10 μg/kg/day to 10 mg/kg/day, which encompasses the oral reference dose of 50 
μg/kg/day. For subsequent cultures comparing the effects of E2 and BPA in 
combination with ICI 182,780 (Tocris), PND1 pituitaries were cultured as described 
above. Pituitaries were placed in one of seven treatment groups; control (0.2% ethanol), 
E2 (10-8 M), E2+ICI (10-8 M +10-5 M), BPA (4.4x10-6 M), BPA+ICI (4.4x10-6 M + 10-5 M), 
and ICI (10-5 M). Four individual experiments were conducted consisting of control, E2, 
and E2+ICI for a total of 6-9 pituitaries for each male and female group. Five individual 
experiments were conducted consisting of control, BPA, BPA+ICI, and ICI for a total of 
6-9 pituitaries for each male and female group. Cultures were harvested 48 hours post-
treatment for analysis. This time was chosen to maximize the possibility of seeing 
changes in genes that were directly or indirectly regulated by E2 or BPA. 
17β-Estradiol and BPA Dosing Experiments 
Neonatal CD-1 mice were dosed orally with 50 μg/kg/day of 17β-estradiol (E2) 
(Tocris) dissolved in tocopherol-stripped corn oil (MP Biomedicals) or 0.1% ethanol in 
corn oil as a control. Pups were dosed orally once daily from PND0 to PND7 and 
pituitaries were collected on the morning of PND7, one hour after the last treatment. A 
total of 6-8 pituitaries spanning three litters for each group were analyzed. For BPA 
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dosing experiments, mice were dosed during the same period with either 50 mg/kg/day 
BPA (Aldrich ≥ 99% purity) or 0.5% ethanol in corn oil. Two liters were individually 
dosed with control and two with BPA, giving 7-14 pituitaries for each group. 
Statistical Analysis: 
Statistical significance was determined using a two-tailed t-test in Microsoft Excel 
for qRT-PCR and cell counting.  P values less than 0.05 were considered statistically 
significant. For culture experiments, a one-way ANOVA was performed and groups 
were compared via Tukey HSD test. 
Results: 
Lhb and Fshb mRNA levels are higher in neonatal females than males 
In this study, we sought to determine the baseline differences between males 
and females during the critical neonatal period of pituitary development prior to 
exploring hormonal regulation of pituitary gene expression. To address this question, 
pituitaries were collected on the day of birth (PND0) for RNA analysis and histology 
from CD-1 mice. At PND0, mRNA levels for luteinizing hormone beta (Lhb) and follicle 
stimulating hormone beta (Fshb) were significantly higher in females than in males as 
assessed by quantitative RT-PCR (qRT-PCR) (Figure 1A). We further characterized the 
expression of other gonadotrope-specific genes in males and females at this age, such 
as gonadotropin releasing hormone receptor (Gnrhr) as well as transcription factors 
necessary for the expression of Lhb and Fshb: forkhead box L2 (Foxl2), early response 
1 (Egr1), and steroidogenic factor 1 (Nr5a1). Expression levels of Foxl2, Erg1, and 
Nr5a1 were not significantly different between the sexes; however, the level of Gnrhr in 
females was slightly lower than in males. Thus, mRNA levels of these genes did not 
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explain why Lhb and Fshb mRNA was higher in females. Next, to see if gonadotrope 
number was different in males and females, as a possible explanation for the difference 
in Lhb and Fshb mRNA, we performed immunohistochemistry for LHβ in PND0 males 
(Figure 1B) and females (Figure 1C) and counted the number of cells, which are 
represented as the percent positive cells (Figure 1D). There was no sexual dimorphism 
in the number of gonadotrope cells at PND0.  
Transcriptional profiling identifies Icam5 as a differentially expressed gene between 
males and females in the pituitary 
To determine what other differences exist between male and female mouse 
pituitaries at the mRNA level that may explain variations in levels of Lhb and Fshb, we 
performed a microarray analysis of male and female PND1 pituitaries. Table 2 shows 
the differentially expressed genes with a p-value of 0.06 or less. Only eight genes were 
found to be significantly different by the microarray, most of which are sex-chromosome 
linked genes. We found only two somatic chromosomal genes that exhibited significant 
differences between the sexes: Lhb and Icam5.  A difference in Fshb expression was 
near significance. Therefore, we chose Lhb, Fshb, Eif2s3x, and Icam5 for further 
analysis (underlined genes Table 2). These genes were compared in males and 
females, by qRT-PCR at PND0, PND4, PND9, PND20, and Adult (6 weeks old, females 
in diestrus). Lhb (Figure 2A) and Fshb (Figure 2B) followed similar expression patterns 
over the postnatal period with higher expression in females than males from PND0 to 
PND9, but lower expression in females at PND20 and the adult. The differences 
between male and female Lhb and Fshb mRNA levels in the adult appear to be due to 
both increasing levels of Lhb and Fshb in males and decreasing Fshb in females. These 
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mRNA expression patterns of Lhb and Fshb correlate to LH and FSH serum levels over 
the postnatal period (Dohler & Wuttke 1975). Icam5 expression was not different 
between males and females at PND0, but was higher in females from PND4-PND20 
and lower in females at the adult time point (Figure 2C). Expression of Icam5 peaks at 
PND9 in both males and females. The X-linked gene Eif2s3x was always more highly 
expressed in the female and expression of this gene did not change greatly over time 
(Figure 2D). Taken together, these data demonstrate that Icam5 mRNA is dynamically 
regulated over time in a sex-specific manner. 
Icam5 is expressed in the anterior pituitary of neonatal mice, mainly in gonadotropes 
Icam5 (telencephalin) has been reported as a telecephalon-specific adhesion 
molecule and its expression in the pituitary has never been documented. Therefore, we 
performed in situ hybridization (ISH) to elucidate the expression pattern of this gene in 
the anterior pituitary at PND9-11 when the expression levels of Icam5 were highest and 
most different between males and females (Figure 2C). We observed that Icam5 
localized to isolated cells in the anterior lobe in males (Figure 3A) and more strongly in 
females (Figure 3B), which correlates well with the qRT-PCR data (Figure 2C). 
Similarly, ICAM5 protein was expressed in the anterior lobe of the pituitary and it 
appeared to be more highly expressed in the female (Figure 3D) than the male (Figure 
3C). Next, immunohistochemistry was used to co-localize ICAM5 with pituitary 
hormones. At PND9, ICAM5 is rarely expressed in TSHβ expressing thyrotropes (Figure 
3E) and POMC expressing corticotropes (Figure 3F).  Although occasional GH 
expressing somatotropes were double-labeled (Figure 3G), many, but not all LHβ 
expressing gonadotrope cells (Figure 3H) contain ICAM5. In the adult, most ICAM5 
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positive cells were gonadotropes (Figure 3J). Prolactin co-localization was also 
performed in the adult due to low detection levels neonatally and was rarely co-localized 
with ICAM5 (Figure 3I). Therefore, the main cell type that ICAM5 is expressed in is the 
gonadotrope population. Importantly, Icam5 mRNA was also expressed in the human 
brain and pituitary, as assessed by RT-PCR analysis (data not shown), indicating that 
expression and regulation of this gene could be important in human physiology. 
Regulation of Icam5 may occur directly at the level of the pituitary 
To see if exposure to exogenous estrogenic compounds could alter expression of 
sexually dichotomous genes, we isolated pituitaries at PND1, which is a time point at 
which expression of these genes is sexually dichotomous in vivo, and treated them with 
E2 and BPA. First, to determine if the pituitary would be responsive to E2 in culture, we 
looked at the ability of E2 to regulate expression of Cckar, a known estrogen responsive 
gene (Kim et al. 2007). E2 increased Cckar mRNA levels (Figure 6A) indicating that the 
cultured pituitary is able to respond to estrogenic stimuli in vitro. To see if the 
xenoestrogen, BPA, would similarly increase Cckar mRNA and to determine the dose of 
BPA inducing the strongest estrogenic effect, we performed a dose response for BPA 
and observed that 4.4x10-6M BPA induced Cckar mRNA to the greatest extent (Figure 
4A). Therefore, we chose this dose for all further BPA cultures. To determine if BPA is 
acting through estrogen receptors ESR1 or ESR2, pituitaries were co-treated with the 
estrogen receptor antagonist ICI 182,780, which blocks signaling through ESR1 and 
ESR2 (Wakeling 2000). However, this compound has also been shown to activate the 
G-protein coupled estrogen receptor GPER (Filardo et al. 2000). Expression of Cckar 
mRNA was examined in pituitary explants treated with control, BPA, BPA+ICI, and ICI 
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alone (Figure 4B). BPA increased Cckar mRNA levels, ICI was able to block this 
increase, and ICI alone had no effect on gene expression. These data show that the in 
vitro whole organ pituitary explants are a good system to study the regulation of 
estrogen-responsive gene expression. 
Next, to see if estrogen could regulate expression of sexually dichotomous genes 
directly at the pituitary, we treated pituitaries at PND1 with E2, BPA, ICI, or a 
combination of these compounds. In the male, E2 was unable to alter levels of Lhb and 
Fshb (Figure 5A). In contrast, in the female, E2 significantly decreased expression of 
Lhb and Fshb (Figure 5B). This indicates that there is a difference in the way male and 
female pituitaries respond to E2 in vitro. Interestingly, treatment with BPA was unable to 
alter expression of Lhb or Fshb in males (Figure 5C) or females (Figure 5D), showing 
that BPA does not act exactly like E2 in regulation of Lhb or Fshb, despite its ability to 
alter Cckar expression. 
Lastly, we examined the direct effect of E2 and BPA on the expression of Icam5 
in the pituitary. E2 decreased expression of Icam5 and co-treatment with ICI blocked 
this effect in males (Figure 6A) and in females (Figure 6C). BPA treatment also 
decreased expression of Icam5 in both males (Figure 6C) and females (Figure 6D) 
similarly to E2 and co-treatment with ICI blocked the decrease in males (Figure 6C) but 
only partially blocked the decrease in females (Figure 8D). ICI alone had no effect in 
males or females (Figure 6C, D). Finally, to show that suppression of Icam5 by BPA 
occurs in a dose-dependent manner, we examined Icam5 mRNA levels in the samples 
used for the Cckar dose response curve (Figure 4A). BPA decreased expression of 
Icam5 at the 4.4x10-6 M and 4.4x10-5 M concentrations, but did not significantly reduce 
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expression at the 4.4x10-7 M or 4.4x10-8 M concentrations, demonstrating a dose-
dependent effect of BPA on Icam5 expression (Figure 6E). Taken together, these data 
demonstrate that E2 and BPA can both decrease expression of Icam5 mRNA directly at 
the pituitary in males and females, however some of this suppression may come from a 
pathway other than an ER-mediated pathway. This is in contrast to Lhb and Fshb that 
were only significantly regulated by E2 at the level of the pituitary in females and were 
unaffected by BPA. Thus, some gene expression can be regulated directly at the level 
of the pituitary in a sexually dichotomous manner and BPA does not have identical 
effects to that of E2. 
Neonatal exposure to E2 or BPA can influence the levels of sexually dichotomous 
genes in vivo 
Since E2 and BPA were able to regulate expression of sexually dichotomous 
genes in vitro, we next determined if these effects were translatable to an in vivo 
scenario. Neonatal mice were orally dosed for one week (PND0 to PND7) with 50 
μg/kg/day of E2, which is a dose sufficient to regulate expression of estrogen 
responsive genes: progesterone receptor (Pgr) and cholecystokinin A receptor (Cckar) 
(data not shown) or 50 mg/kg/day BPA, which is the Lowest Observed Adverse Effect 
Level (LOAEL) for BPA and was similar to the effective dose used in vitro. E2 was 
sufficient to suppress levels of Lhb and Fshb mRNA, which are genes known to be 
regulated by E2 in the adult (Shupnik et al. 1988) in both males (Figure 7A) and females 
(Figure 7B). Interestingly, we found that E2 treatment also reduced levels of Icam5 in 
both males and females (Figure 7A, B), demonstrating that E2 may play a role in 
regulation of Icam5 transcription in vivo. Exposure to BPA during the neonatal period 
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had a sex specific effect. BPA significantly decreased the levels of Icam5 in females 
(Figure 7D), however, males were unaffected by exposure (Figure 7C). Lhb and Fshb 
were not significantly affected by BPA during this time period in males (Figure 7C) or 
females (Figure 7D), which is similar to in vitro data (Figure 5 C-D). Thus, Icam5 can be 
regulated in part by estrogenic exposure during the critical neonatal period and BPA can 
alter its expression in a sex specific manner. 
Discussion 
BPA is thought to cause reproductive health effects due to HPG axis disruption 
and mediates numerous sex specific outcomes. However, little is known about any 
potential sexual dichotomy at the level of the pituitary gland. Therefore, we documented 
sex differences in gene expression during the critical neonatal period of pituitary 
development and determined if E2 and BPA could alter expression of genes expressed 
differently between the sexes. In this study, we found a few genes to be differentially 
expressed between male and female pituitaries at PND1. These genes were Lhb, Fshb, 
and a novel gene to the pituitary, Icam5. E2 attenuated Lhb and Fshb gene expression 
in females both in vitro and in vivo, but only suppressed these genes in vivo in males. In 
contrast, Icam5 was suppressed in males and females both in vitro and in vivo by E2. 
BPA was unable to suppress Lhb and Fshb mRNA, but did suppress Icam5 similarly to 
E2 in both sexes in vitro. In vivo, BPA only suppressed Icam5 in females. Thus, the 
neonatal pituitary is sensitive to hormonal and chemical stimuli that can potentially 
disrupt expression of sexually dichotomous genes within the pituitary, potentially 
contributing to negative effects on reproduction seen with BPA treatments (Maffini et al. 
2006; Wang et al. 2014). 
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Gonadotrope subunit mRNAs represent the main sex difference in the neonatal 
pituitary.  The higher levels of Lhb and Fshb mRNA observed in females correspond 
with previous studies showing higher LH and FSH serum levels in females (Poling & 
Kauffman 2012). However, the differences in Lhb and Fshb mRNA does not seem to be 
due to mRNA levels of other transcription factors regulating these genes, indicating the 
difference likely exists at the level of the hypothalamus or in protein levels not examined 
in our study. Additionally, at PND1 gonadotrope cell number between males and 
females was similar, which is in agreement with previous studies (Dihl et al. 1988; Chen 
1988). However, another study did indicate that there are more gonadotrope cells in 
females at PND5 (Ishikawa et al. 2014). This discrepancy may be due to the age of the 
mice or the method of staining (colormetric vs. fluorescence). If it is the age, it is 
possible that sex differences in cell number do not develop till a later time point. It is 
somewhat surprising that we uncovered few other sex differences in the neonatal 
pituitary via microarray analysis. In the adult pituitary more differences were found via 
serial analysis gene expression (SAGE) (Nishida et al. 2005). This discrepancy may be 
due to age of the pituitary or technique used to probe gene expression. Furthermore, 
the pituitary consists of a very heterogeneous population of cells. It may be difficult to 
detect changes that occur only in one small population of cells within the pituitary. 
Gonadotropin subunit mRNAs can be regulated by E2 throughout the lifespan. 
Our data show that, at the level of the pituitary, E2 decreased expression of Lhb and 
Fshb in females, however, not in males. This sex-specific effect in vitro may suggest 
that the neonatal male pituitary is programmed in such a way to make it unable to 
respond to E2 directly at the level of the pituitary. Males are exposed to greater 
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hormonal stimuli during the perinatal testosterone surge. This surge has been shown to 
cause epigenetic changes in the brain possibly leading to permanent modifications, 
such as sexually dichotomous expression of Esr1 mRNA (DonCarlos et al. 1995) and 
sex differences in the DNA methylation pattern of the Esr1 promoter (Kurian et al. 2010; 
Tsai et al. 2009). Our data suggest that the pituitary also experiences gender-specific 
changes that modify the direct response of the pituitary to E2. These modifications are 
not necessarily permanent and can be reprogrammed across the lifespan (Schwarz et 
al. 2010; Nugent et al. 2015), therefore, it is possible that a male pituitary could directly 
respond to E2 at a different age.  
Surprisingly, exposure to BPA did not affect transcription of Lhb or Fshb in 
neonatal males or females. Embryonic BPA exposure has been shown to alter 
expression of Lhb and Fshb in vivo (Xi et al. 2011; Brannick et al. 2012), therefore, it 
could be that the embryonic period is more sensitive to exposure to BPA. However, 
neonatal BPA exposure has been shown to decrease GnRH induced LH serum levels, 
indicating that BPA may be affecting LH release during this time period in concert with 
GnRH stimulation (Fernandez et al. 2009). Prolactin, another important pituitary derived 
hormone, exhibits increases in expression and release by exposure to both E2 and BPA 
in the adult (Steinmetz et al. 1997). In a previous study, embryonic exposure to BPA did 
not increase expression of prolactin at birth, which is the time point at which we are 
isolating pituitaries for culture analysis (Brannick et al. 2012). Although we have not 
analyzed prolactin expression because it was not detected as sexually dichotomous at 
this time point on our array, we cannot rule out that it would not be regulated by E2 or 
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BPA neonatally. Taken together, there are age dependent effects of environmental 
exposures on several pituitary hormones. 
One of the most significant findings of our study is the sex-specific expression 
pattern of Icam5 mRNA and protein in the pituitary. ICAM5 is characterized as a 
telencephalon-specific cell adhesion molecule (Yoshihara et al. 1994). It is expressed in 
the soma-dendritic membrane of spiny neurons in the mammalian telencephalon, but 
not the axonal membrane and is absent from other brain regions and the spinal cord 
(Yoshihara et al. 1994; Benson et al. 1998; Mitsui et al. 2005; Kelly et al. 2014). Our 
data indicate that ICAM5 is also expressed in the anterior pituitary gland, and its 
expression appears greater in females than males (Figure 3). The cell type where we 
see the greatest expression of ICAM5 is the gonadotrope cells, possibly indicating that 
this adhesion molecule could be contributing to differences in LH and FSH serum levels 
between males and females (Poling & Kauffman 2012). Icam5 mRNA is not readily 
expressed in the embryo, but begins to be expressed at birth and reaches maximal 
levels at PND10/PND9 in the brain (Yoshihara et al. 1994) and the pituitary (Figure 2C). 
This timing corresponds with the timing of dendritic development and synapse formation 
in the brain (Mori et al. 1987; Imamura et al. 1990) and active pituitary gland expansion 
(Taniguchi et al. 2002; Carbajo-Perez & Watanabe 1990). The dynamic expression of 
Icam5 mRNA over time, especially in females, may indicate hormonal regulation similar 
to Lhb and Fshb. The ability of E2 to decrease Icam5 expression was confirmed in both 
males and females, and the regulation appears to occur at the level of the pituitary. The 
mechanism of action likely takes place through an ESR1- or ESR2- mediated pathway 
as co-treatment with ICI inhibited this decrease in both males and females (Wakeling 
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2000). This shows that Icam5 expression can be regulated by classical estrogen 
signaling pathways that are very important for proper transcription and hormone release 
within the pituitary.  
The xenoestrogen BPA is also capable of decreasing Icam5 expression in both 
males and females at the level of the pituitary. However, ICI did not fully block this effect 
in females, suggesting that Icam5 can potentially be regulated by BPA via mechanisms 
other than ESR1 or ESR2. One potential pathway would be through the G-protein 
coupled receptor, GPER (Thomas & Dong 2006). Additionally, BPA has also been 
shown to act via androgen receptor, thyroid hormone receptor, estrogen-related 
receptor gamma, and aryl hydrocarbon receptor (Okada et al. 2008; Sohoni & Sumpter 
1998; Kruger et al. 2008; Moriyama et al. 2002). However, we do know that BPA can 
act at ESR1 in the pituitary because BPA induced expression of Cckar (Figure 4), which 
is an ESR1 regulated gene (Kim et al. 2007) and this increase was fully blocked by ICI. 
Therefore, BPA likely has multiple pathways of action within the pituitary, as well as 
actions in the HPG axis that will subsequently influence the pituitary. BPA in vivo was 
only able to decrease Icam5 in females and not males. This is similar to the sex specific 
effects seen with embryonic BPA treatment (Brannick et al. 2012). Since BPA was able 
to decrease Icam5 in vitro but not in vivo in males, it is possible that signals from the 
hypothalamus may either protect the male pituitary or counteract the actions of BPA. It 
is also possible that since levels of Icam5 are lower in males in vivo than females that 
BPA is unable to reduce Icam5 further. Therefore, it is possible that BPA can regulate 
LH and FSH levels by changing Icam5 expression and possibly interfering with either 
response to GnRH or release of LH and FSH. 
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Although the function of ICAM5 in the pituitary is unknown, its roles in the brain 
as a cell adhesion molecule have been extensively studied. ICAM5 is abundantly 
expressed in the dendritic filopodia and plays an important role in synapse formation 
with presynaptic axons, via the extracellular matrix molecule, vitronectin (Furutani et al. 
2012), and/or β1 integrins (Tian et al. 2000; Ning et al. 2013). Once these connections 
are established, the extracellular domain of ICAM5 is cleaved, disrupting the 
cytoplasmic actin cytoskeleton through to α-actinin or ERM (ezrin/radixin/moesin) 
proteins promoting reorganization to induce spine maturation (Tian et al. 2007; Tian et 
al. 2000; Matsuno et al. 2006; Nyman-Huttunen et al. 2006; Tsukita & Yonemura 1999; 
Furutani et al. 2012). Based on the role of ICAM5 in cell adhesion and its ability to alter 
the actin cytoskeleton, we propose that ICAM5 may play a role in structural organization 
of functional homotypic cell networks within the pituitary. These cell networks in the 
pituitary are important because they set up the ability of the pituitary cells to have proper 
hormone release (Le Tissier et al. 2012; Bonnefont et al. 2005; Budry et al. 2011). Cells 
and cell networks can also adjust in response to external stimuli. For example, GnRH 
signaling in gonadotrope cells can cause actin reorganization, resulting in membrane 
projections and cellular migration towards blood vessels (Navratil et al. 2007). 
Interestingly, pituitary cell networks can also exhibit sex differences. For example, a 
higher proportion of somatotrope cells respond to growth hormone releasing hormone 
(GHRH) in males than in females (Sanchez-Cardenas et al. 2010). It is possible that 
something similar may be happening with the gonadotrope population due to expression 
of ICAM5. Also, cell networks can be regulated by hormonal mechanisms because 
gonadectomy alters the responsiveness of cells to GHRH, including hormone release 
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and cell motility (Sanchez-Cardenas et al. 2010; Schaeffer et al. 2011). In 
gonadotropes, GnRH treatment leads to an increase in process extension, which is 
enhanced by prior E2 exposure (Alim et al. 2012). Therefore, it is evident that sex 
differences can exist in pituitary networks and these networks can be regulated by 
gonadal hormones. However, the mechanism behind these observations has yet to be 
elucidated. Our data provide one potential adhesion and cytoskeletal modifying 
molecule that is regulated by E2 and BPA in the pituitary, ICAM5. Neonatal exposure to 
BPA caused decreased basal LH secretion as well as decreased amount of LH release 
in response to GnRH (Fernandez et al. 2009). Thus, if ICAM5 is important in the 
function of pituitary networks, which are necessary for proper response to signals from 
the hypothalamus and subsequent hormone release, disruption of ICAM5 via BPA could 
be responsible for negative impacts on reproductive health directly at the pituitary. 
Further investigation into the role of ICAM5 in the pituitary is warranted. 
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Table 1. Antibodies used in study. 
 
 
Peptide/protein 
target 
Antigen 
sequence (if 
known) 
Name of 
Antibod
y 
Manufacture
r, catalog #, 
and/or name 
of individual 
providing 
the antibody 
Species 
raised in; 
monoclonal 
or polyclonal 
Dilution 
used 
 Rat Beta 
Luteinizing 
Hormone 
N/A 
anti-
rBetaLH-
IC 
National 
Hormone and 
Peptide 
Program 
(NHPP) Dr. 
A.F. Parlow 
rabbit; 
polyclonal 
Paraffin 
1:1000 
Frozen 1:50 
Mouse ICAM5 
(TLCN) 
AEGGAETPG
TAESPADGE
VFAIQLTSS 
anti-
TLCN-C 
Dr. Yoshihiro 
Yoshihara 
rabbit; 
polyclonal 
1:4000 
Rat Beta Thyroid 
Stimulating 
Hormone 
N/A 
anti-
rBetaTS
H-IC-1 
National 
Hormone and 
Peptide 
Program 
(NHPP) Dr. 
A.F. Parlow 
rabbit; 
polyclonal 
1:1000 
Rat 
Adrenocorticotro
pic Hormone 
N/A 
anti-
rACTH 
National 
Hormone and 
Peptide 
Program 
(NHPP) Dr. 
A.F. Parlow 
rabbit; 
polyclonal 
1:1000 
Rat Growth 
Hormone 
N/A anti-rGH 
National 
Hormone and 
Peptide 
Program 
(NHPP) Dr. 
A.F. Parlow 
rabbit; 
polyclonal 
1:1000 
Rat Prolactin N/A 
Anti-
rPRL 
National 
Hormone and 
Peptide 
Program 
(NHPP) Dr. 
A.F. Parlow 
rabbit; 
polyclonal 
1:1000 
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Figure 1. Lhb and Fshb mRNA levels were higher in females than males at PND0, but 
gonadotrope cell number was the same. Females showed elevated levels of Lhb and 
Fshb compared to males, but levels of transcription factors Foxl2, Egr1, and Nr5a1 were 
the same between sexes and there was a significant but small difference in Gnrhr 
(n=10-15) (A). Immunohistochemistry at PND0 with LHβ marked gonadotrope cells 
(Mag 200x) in males (B) and females (C). Cell counts showed that there were no 
differences in gonadotrope cell number (n=4) (D). Scale bar=50μm. (*)= p-value 0.05. 
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Table 2. Few sex differences discovered in pituitary at PND1 by 
microarray 
Higher in Males 
Gene Fold Change P Value 
Ddx3y 11.6176 4.3006E-11 
Eif2s3y 10.2549 6.8983E-05 
Uty 1.6276 0.0142 
Higher in Females 
Gene Fold Change P Value 
Xist 5.1038 1.6954E-07 
Xist 2.9461 5.5872E-06 
Lhb 3.7814 1.5293E-04 
Eif2s3x 1.5297 0.0218 
Icam5 1.4555 0.0290 
Fshb 2.5616 0.0561 
 
Table 2. Few sex differences discovered in the pituitary at PND1 by microarray. 
Microarray analysis of PND1 control pituitaries showed few genes to be differentially 
expressed between males and females, of which, only three are not sex chromosome 
linked: Lhb, Fshb, and Icam5. Bolded genes were further analyzed and confirmed by 
qRT-PCR analysis. 
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Figure 2. Lhb, Fshb, and Icam5 demonstrated fluctuations in expression over the 
postnatal period. Lhb, Fshb, Icam5, and Eif2s3x were examined at PND0 (n=10-15), 
PND4 (n=7-12), PND9 (n=10-11), PND20 (n=6-7), and 6 week old adults, with females 
taken in diestrus (n=7). Lhb (A) and Fshb (B) were more highly expressed in females 
than males from PND0 to PND9 and less expressed in females by PND20 and in 
adulthood. Icam5 was not different between males and females at PND0, was higher in 
females from PND4 to PND20, and was lower in females in the adult (C). Eif2s3x was 
higher in females than males at all timepoints examined (D). (*)= p-value 0.05. 
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Figure 3. Icam5 was expressed more strongly in the anterior pituitary of females than 
males at PND9 and mainly expressed in gonadotrope cells. In situ hybridization shows 
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Figure 3 continued: expression of Icam5 mRNA in isolated cells in the anterior pituitary 
of males (A) and stronger expression in females (B) at PND9 (n=3). 
Immunohistochemistry for ICAM5 shows similar expression in the anterior lobe of males 
(C) and stronger expression in females (D) at PND9 (n=3). Arrows denote positive cells. 
Double IHC shows ICAM5 is rarely expressed in thyrotropes (E) and corticotropes (F), 
occasionally expressed in somatotropes (G) and mainly expressed in gonadotrope cells 
in PND9 females (H). In the adult ICAM5 is rarely expressed in lactotrope cells (I) and 
continues to be mainly expressed in gonadotrope cells (J) of randomly cycling adult 
females.  Scale bar=50μm 
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Figure 4. 17β-Estradiol (E2) and Bisphenol A (BPA) increased expression of Cckar, in 
vitro. Whole organ pituitary cultures treated with 10-8M E2 and doses of BPA from 
4.4x10-8M to 4.4x10-5M. Cckar expression was significantly increased with E2, BPA 10-
7M, BPA 10-6M, and BPA 10-5M with the highest induction by BPA at the 10-6M 
concentration (A). In whole organ pituitary cultures treated with BPA, ICI, or a 
combination of the two, BPA (10-7M) increased expression of Cckar, co-treatment of 
BPA+ICI blocked this increase, and ICI alone had no effect (B) (n=4-5) (*)= p-value 
0.05. 
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Figure 5. 17β-Estradiol (E2) and Bisphenol A (BPA) had different effects on Lhb and 
Fshb mRNA levels in vitro. Pituitaries treated in vitro with E2 (10-8M) showed no 
significant change in Lhb or Fshb levels compared to controls in males (A), however E2 
decreased expression of Lhb and Fshb significantly in females (B) (n=6-9). Pituitaries 
treated in vitro with BPA (4.4x10-6M) showed no significant change in Lhb or Fshb in 
males (C) or females (D) (n=6-9) (*)= p-value 0.05. 
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Figure 6. 17β-Estradiol (E2) and Bisphenol A (BPA) decreased expression of Icam5 in 
vitro. Pituitaries treated in vitro with E2 (10-8M) showed decreased expression of Icam5, 
this decrease was inhibited by co-treatment of E2+ICI in males (A) and females (B) 
(n=6-9). Pituitaries treated with BPA (4.4x10-6M) demonstrated decreased expression of 
Icam5 which was blocked fully by co-treatment of BPA+ICI in males (C), but only 
partially blocked the decrease in females (BPA+ICI significantly lower than control in 
females) (D). ICI alone had no effect in males (C) or females (D) (n=6-9). A dose 
response curve showed that BPA decreased expression of Icam5 at the 10-6M and 10-
5M concentrations, but had no effect at lower concentrations in vitro (n=4-5) (E) (*)= p-
value 0.05 
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Figure 7. 17β-Estradiol (E2) decreased expression of Lhb, Fshb, and Icam5 in vivo and 
Bisphenol A (BPA) decreased expression of Icam5 in females only. Mice dosed from 
PND0-PND7 with 50 μg/kg/day E2 showed lower expression of Lhb, Fshb, and Icam5 in 
males (A) and females (B) at PND7 compared to control (n=6-8). Mice dosed with 50 
mg/kg/day BPA showed no change in Lhb, Fshb, or Icam5 in males (C), but showed a 
slight repression of Icam5 in females (D). (*)= p-value 0.05. 
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Chapter 3: Effects of exposure to the endocrine disrupting chemical, bisphenol A, 
during critical windows of murine pituitary development 
 
 
 
 
Abstract:  
 
Critical windows of development are quite sensitive to endocrine disruption. The 
murine pituitary gland has two critical windows of development: embryonic gland 
establishment and neonatal hormone cell expansion. During embryonic development, 
one environmentally ubiquitous endocrine disrupting chemical (EDC), bisphenol A 
(BPA), has been shown to alter pituitary development by increasing proliferation and 
gonadotrope number only in females. However, the effects of embryonic dosing on 
neonatal development and the effects of exposure during the neonatal period were not 
examined. Therefore, in this study, we first examined mice exposed to BPA during the 
embryonic period and found no change in proliferation and gonadotrope number at 
PND4 in females. Next, we dosed pups from postnatal day (PND) 0 to PND7 with 0.05, 
0.5, and 50μg/kg/day BPA, environmentally relevant doses, or 50μg/kg/day estradiol 
(E2). Mice were collected after dosing at PND7 and at five weeks. Mice dosed 
neonatally with BPA did not have the same effects as embryonic exposure, but did have 
new effects, some being sex specific. Pituitary Pit1 mRNA expression was decreased 
with BPA 0.05 and 0.5μg/kg/day in males only. Expression of Pomc mRNA was 
decreased at 0.5μg/kg/day BPA and E2 in males and 0.5, 50μg/kg/day BPA, and E2 in 
females, however, there were no noticeable corresponding changes in protein 
expression. At 5 weeks, minimal changes confined to females were detected. These 
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data demonstrate that BPA exposure during different critical windows of pituitary 
development has unique sex specific effects on gene expression. 
Introduction:  
The pituitary is the master gland of the endocrine system, releasing hormones 
that control reproduction, lactation, growth, metabolism, and stress. To release these 
hormones, the anterior pituitary must develop five hormone secreting cell types: 
gonadotropes, lactotropes, somatotropes, thyrotropes, and corticotropes. Development 
of the hormone secreting cell types occurs during two key periods in mouse 
development: embryonic and neonatal. During embryonic development, cell 
specification is regulated by intrinsic and paracrine signals from the pituitary and 
surrounding tissue (Davis et al. 2013). However, during the neonatal period, the 
capability for communication between the hypothalamus, pituitary, and target organs 
develops (Pointis & Mahoudeau, 1976; Milkovic et al., 1973), suggesting a potential role 
for axis hormones in this window of development. Additionally, at birth, the testosterone 
surge establishes sex differences in the hypothalamic-pituitary-gonadal (HPG) and the 
hypothalamic-pituitary-adrenal (HPA) axes through local aromatization of testosterone 
to estradiol in the male brain (Homma et al., 2009; McCormick et al., 1998). Thus, the 
endocrine milieu postnatally may alter pituitary sensitivity to exposure to endocrine 
disrupting chemicals (EDCs).  
Bisphenol A (BPA) is an EDC found in several items such as polycarbonate 
plastics, epoxy resins, and thermal paper, leading to ubiquitous exposure (Shelby 
2008). Importantly, studies suggest that developing organs of fetuses and neonates 
have heightened sensitivity to EDCs such as diethylstilbestrol and BPA (Herbst 1981; 
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Markey et al. 2001; Markey et al. 2005). BPA is readily detectible in fetal cord serum, 
maternal serum, and fetal amniotic fluid in humans (Vandenberg et al. 2007), 
demonstrating exposure to BPA during critical developmental windows. A possible 
mechanism by which BPA is considered to act is by disrupting the actions of estrogens. 
The classical estrogen receptors ESR1 and ESR2 and the membrane G protein-
coupled estrogen receptor (GPER) are found in the hypothalamus and pituitary 
(Nishihara et al. 2000; Ogasawara et al. 2009; Hazell et al. 2009; Mitra et al. 2003; 
Merchenthaler et al. 2004). However, the roles of estrogen signaling and potential 
effects of BPA during neonatal pituitary development are unexplored. 
Developmental exposure to environmentally relevant doses of BPA can 
adversely affect every axis of the endocrine system regulated by the pituitary gland, 
including the reproductive axis (Losa-Ward et al. 2012; Monje et al. 2010; Fernandez et 
al. 2009; Wang et al. 2014; Howdeshell et al. 1999), prolactin levels (Khurana et al. 
2000), the growth axis (Ramirez et al. 2012), the thyroid axis  (Zoeller et al. 2005), and 
the stress axis  (F. Chen et al. 2014). BPA also alters sex differences of the HPG and 
HPA axis established by sex steroids (Patchev et al., 1995; Chen et al., 2014; Rubin et 
al., 2006; Cao et al., 2012). Despite the relatively quick metabolism of BPA (Stahlhut et 
al. 2009), changes can sometimes be seen well after exposure has ended. For 
example, embryonic exposure to BPA led to reproductive tissue weight changes in adult 
females and changes in estrogen and progesterone receptor expression (Markey et al. 
2005). Also, neonatal exposure to BPA had different outcomes on the hypothalamus 
two days after exposure than eight days after exposure (Cao et al. 2012), indicating the 
importance of examining multiple time points after exposure. Therefore, it is clear that 
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developmental exposure to BPA can influence sex differences and the endocrine axes, 
though regulation may be time and/or context specific. Despite this evidence, few 
studies have closely examined the effects of neonatal BPA exposure on development 
and expression of genes in the pituitary itself.  
Previously, our laboratory showed that embryonic exposure to BPA increased 
pituitary proliferation and gonadotrope cell number in female offspring (Brannick et al. 
2012), which is a response similar to that of estradiol (E2) (Wu et al. 2009). However, 
the effect of embryonic or neonatal exposure on the second wave of pituitary 
development is unknown. We hypothesized that BPA exposure would have different 
effects on the pituitary depending on gender, the developmental period of exposure, 
and the time examined after exposure. To test this hypothesis, two experiments were 
performed: first we examined pituitaries exposed to BPA embryonically at PND4 to 
determine the effects on neonatal pituitary development. Second, we examined 
pituitaries at two time points after exposure neonatally to three environmentally relevant 
doses of BPA and E2 and compared male and female effects.  
Materials and methods: 
Experiment 1 Design: Effects of embryonic dosing on neonatal pituitary development 
This experiment examined whether the increased proliferation and gonadotrope 
number seen in females as a result of embryonic dosing of BPA would be maintained 
during the neonatal developmental period in the absence of BPA. Timed pregnancies of 
mice on a mixed FVB, C57BL/6 background were generated and orally dosed with 
control, 0.5µg/kg/day BPA, or 50µg/kg/day of BPA dissolved in ethanol and diluted in 
tocopherol stripped corn oil as previously described (Brannick et al. 2012) from 
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embryonic day 10.5 to 18.5. Pups were collected for immunohistochemistry at PND0. 
Another cohort of mice was dosed similarly and one female offspring from each dam 
was collected on PND4, a time at which the pituitary is rapidly expanding (Wang et al. 
2014; Carbajo-Perez & Watanabe 1990). The University of Illinois Urbana-Champaign 
Institutional Animal Care and Use Committee approved all procedures. 
Experiment 2 Design: Effects of neonatal dosing 
This experiment examined the effects of dosing males and females during the 
critical neonatal period of pituitary development. Here, CD-1 mice, obtained from 
Charles Rivers, were bred in house and maintained as described (Weis & Raetzman 
2016). Sex was confirmed by visual inspection and gonad removal. Litters were culled 
to 8-12 pups and neonatal pups were dosed orally through consumption from a pipet tip, 
once daily, from postnatal day (PND)0 to PND7 with control (0.1% EtOH), 0.05, 0.5, or 
50μg/kg/day bisphenol A (BPA) (referred to as BPA0.05, BPA0.5, and BPA50 
respectively) (Aldrich ≥ 99% purity), or 50μg/kg/day 17β-estradiol (E2) (Tocris) dissolved 
in tocopherol-stripped corn oil (MP Biomedicals). The 0.05 and 0.5 μg/kg/day doses of 
BPA were chosen because they fall within the range of human exposure levels (Lakind 
& Naiman 2008). The 50μg/kg/day dose of bisphenol A was chosen because it is the 
oral reference dose for BPA. The 50μg/kg/day dose of E2 was chosen because it was a 
dose that was sufficient to induce expression of estrogen regulated genes in our 
system. One male and one female were taken from each litter at each time point. Six 
separate litters were dosed with each compound, each n represents a different litter. 
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Part A. On neonatal pituitary development 
This part of the experiment examined the immediate effects of exposure to BPA 
and E2 during the neonatal period. Mice were harvested on PND7, one hour after the 
final dosing. For western blot analysis, an additional dosing of each compound was 
performed and all pups were collected at PND7 for western blot analysis. 
Part B. At five weeks 
This experiment examined whether neonatal dosing would influence the pituitary 
outside the first postnatal rapid growth phase, which ends at 3 weeks of age (Gremeaux 
et al. 2012). Here, five-week old siblings of the mice examined at PND7 were collected 
for RNA analysis. One male and female were analyzed from each litter, if possible. Due 
to sex distribution, it was not always possible to have an n of 6. The estrous cycles were 
monitored beginning at five weeks by vaginal smears and mice were euthanized when 
in estrus. Female mice were euthanized in estrus because neonatal E2 treatment 
caused persistent estrus. 
Measurements, Weight, and Puberty Assessment 
Weights and measurements were taken of mice at PND7 and five weeks to 
determine if there were any gross systemic effects of BPA or E2 exposure.  Wet weights 
for testes, ovaries, uteri, and liver were all compared to body weight. Anogenital 
distance was measured and compared to body weight. Puberty measurements were 
observed by the day of vaginal opening for females and preputial separation for males.  
Immunohistochemistry:  
PND0 and PND4 heads were fixed overnight in 3.7% formaldehyde in PBS at 
4ºC. Heads were then dehydrated in a series of graded ethanol at room temperature 
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and embedded in paraffin. Paraffin blocks were sectioned 6µm thick. For PND4 
pituitaries, LHβ and Ki67 staining was performed as previously described (Brannick et 
al. 2012). Three slides evenly spaced spanning the entire pituitary from three female 
pups all from separately dosed litters were stained with anti-LHβ antibody (1:1000, 
National Hormone and Pituitary Program) and anti-Ki67 antibody (1:500, BD 
Pharmingen). The number of LHβ positive cells were counted and divided by the total 
number of cells in the anterior lobe. Sections on a slide, as well as slides per animal, 
were averaged together to obtain the mean % positive LHβ cells. The number of Ki67 
positive cells lining both the intermediate lobe cleft and the anterior lobe cleft were 
counted and divided by the total number of cells lining the intermediate lobe cleft and 
the anterior lobe cleft, respectively. Average % positive Ki67 cells lining the cleft was 
determined for each animal. Only cells lining the cleft were counted as this location 
generally harbors the pituitary progenitor cells, which were the cells determined to be 
experiencing increased proliferation with BPA treatment at PND0 previously described 
(Brannick et al. 2012). All experiments contained a slide without primary antibody to 
ensure specificity. The TUNEL Kit (Roche) was used to determine cell death. Positive 
cells from three sections evenly spaced from three female pituitaries were counted to 
determine cell death at both PND0 and PND4. All experiments were performed with a 
no enzyme slide as a control. Positive cells were averaged on a slide then averaged for 
the animal. For all experiments, slides were counterstained with 4’,6-diamidino-2-
phenylindole (DAPI; 1:1000; Sigma) or counterstained with DAPI in mounting media 
(2μg/ml). All immunostaining slides were visualized and processed as previously 
described (Brannick et al. 2012). 
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Quantitative RT-PCR: 
For RNA analysis, males and females were analyzed separately (n=3-6). RNA 
was processed as previously described (Nantie et al. 2014). Expression levels of the 
genes of interest were normalized to Actb mRNA levels, with the primer sequences of 
forward 5’ to 3’: GACATGGAGAAGATCTGGCA and reverse 5’ to 3’: 
GGTCTCAAACATGATCTGGGT (Life Technologies). Gene expression for Mki67, Lhb, 
Nr5a1, Tshb, Gh, Prl was analyzed using primer sequences previously published 
(Brannick et al. 2012) and Pit1 and Tpit previously published (Nantie et al. 2014). 
Finally, Pomc sequences used were forward 5’ to 3’: GATAGCGGGAGAGAAAGCCG 
and reverse 5’ to 3’: GGGACCCCGTCCTGTCCTAT. Proliferating progenitor cells are 
marked by Mki67. Nuclear receptor subfamily 5 group A member 1, Nr5a1, expression 
is found solely in the gonadotrope lineage. Expression of POU domain class 1, 
transcription factor 1, Pit1, is found in the lactotropes, somatotropes, and thyrotropes, 
and T-Box 19, Tbx19, or Tpit is found in the melanotrope cells of the intermediate lobe 
and corticotrope cells of the anterior lobe (McDermott et al. 1999; Li et al. 1990; 
Pulichino et al. 2003). Data were analyzed using the standard comparative ΔCT value 
method as previously described (Goldberg et al. 2011). Individual points were graphed 
with the sex indicated. Outliers were determined by the Grubbs test. Averages are 
shown as a line. 
Western Blot:  
Pituitaries (n=3) were frozen on dry ice and lysed using radioimmunoprecipitation 
assay buffer (RIPA) buffer. Protein fractions were obtained by centrifugation for 5 min at 
4°C at 20817 rcf. Total protein concentration was measured via a BCA protein assay kit 
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(Thermo Fisher) according to the manufacturer’s instructions. Protein samples (20μg) 
were mixed with RIPA buffer and 3x Laemmli loading dye, then heated for 12 minutes at 
57°C. Samples were loaded on a 10% SDS-PAGE gel and transferred to a 
nitrocellulose membrane (BioRad). The membrane was blocked for two hours in 5% 
nonfat dried milk in Tris buffered saline (TBS) then incubated with either PIT1 antibody 
(rabbit, 1:1000, gift from Dr. Simon Rhodes), POMC antibody (rabbit, 1:250, DAKO), 
βACTIN antibody (rabbit, 1:1000, Cell Signaling), or α-TUBULIN antibody (mouse, 
1:5000, Sigma) in 1% milk with 0.2% Tween, overnight at 4°C. Secondary goat anti-
rabbit (1:500) or goat anti-mouse (1:5000) IgG conjugated to IRdye 800cw (LiCor) was 
added at room temperature for one hour. Membrane was then imaged with the Odyssey 
infrared imaging system (LiCor). The relative protein levels were analyzed by NIH 
ImageJ. 
Statistical Analysis: 
Statistical significance between the controls, three BPA treatment groups, and E2 
were determined using a one-way ANOVA. If significance was found, the mean fold 
change between groups were compared using the Tukey HSD test in Microsoft Excel 
for both qRT-PCR and cell counting. P values less than 0.05 were considered 
statistically significant. 
Results: 
Experiment 1: Effects of embryonic dosing on neonatal pituitary development:   
PND4 pituitaries, from female mice dosed embryonically with control or BPA, 
were stained by immunohistochemistry with Ki67 and Ki67 positive cells in the cleft of 
the anterior and intermediate lobes were counted. Percent Ki67 positive cells in the 
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control (Figure 8A; 24.6 ± 2.2% positive), BPA0.5 (Figure 8B; 23.9 ± 0.2% positive), and 
BPA50 (Figure 8C; 23.1 ± 2.3% positive) groups showed no difference in Ki67 in the 
cells lining the cleft. Next, the PND4 pituitaries were stained with LHβ to look at 
gonadotrope number. Percent LHβ positive cells in the control (Figure 8D; 4.5 ± 0.4% 
positive) BPA0.5 (Figure 8E; 4.0 ± 0.3% positive), and BPA50 (Figure 8F; 4.2 ± 0.5% 
positive) groups showed that there was no difference in gonadotrope cell number. To 
determine what other factors were influencing cell number at PND0 or PND4, a TUNEL 
assay was performed to determine if the cells were dying by apoptosis. There appeared 
to be more cell death with BPA treatment at PND0 in the BPA0.5 (Figure 8H) and the 
BPA50 (Figure 8I) groups than the female control (Figure 8G) and this was found to be 
significant by cell counts (Figure 8J). At PND4, there was a trend toward more cell 
death in the BPA treated groups, however, this was not found to be significant (Figure 
8K).  
Experiment 2: Neonatal dosing caused few changes in gross appearance of mice:   
In light of the embryonic period of pituitary development demonstrating sensitivity 
to BPA, we next examined whether exposure to BPA during the neonatal period would 
be sensitive. Organ weights and measurements were taken to determine if any gross 
effects are observed. Testes, ovaries, uteri, and liver weight are shown as percent of 
body weight (Table 3). At PND7, the lowest dose of BPA decreased ovary weight 
compared to control and E2 increased uterine weight compared to control. At five 
weeks, the same weights and measurements were gathered. There were no differences 
in body weights or measurements between any of the treatments at this time (Table 4). 
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Experiment 2: Neonatal exposure to bisphenol A did not affect pituitary proliferation:  
 Exposure to BPA or E2 during the neonatal period had no significant effect on 
pituitary proliferation at PND7, as measured by Mki67 mRNA levels in males (Figure 
9A) and females (Figure 9B). We next examined proliferation at five weeks, to see if 
there would be an effect of neonatal BPA exposure at a later time point. Mki67 mRNA 
levels were not significantly altered by BPA or E2 in males (Figure 9C) or females 
(Figure 9D) at five weeks.  
Experiment 2: Neonatal bisphenol A exposure did not affect gonadotrope lineage gene 
expression:  
To examine if there was any effect of BPA exposure during the neonatal period 
on the gonadotrope lineage, mRNA expression levels of the gonadotrope lineage 
transcription factor Nr5a1 were examined. Neither BPA nor E2 had any effect on Nr5a1 
mRNA levels in males at PND7 (Figure 10A). In females, there was no change in Nr5a1 
mRNA levels with BPA treatment, however there was an increase in Nr5a1 with E2 
treatment (Figure 10B). To explore whether a difference in Nr5a1 mRNA levels would 
exist later, we examined the pituitaries at five weeks. In these mice, males showed no 
difference in Nr5a1 levels with treatment (Figure 10C), however, in females there were 
decreases in Nr5a1 with the BPA0.05 and E2 exposures (Figure 10D).  
To further explore the gonadotrope lineage during neonatal exposure to E2 or 
BPA, Lhb mRNA expression was analyzed. With neonatal dosing, BPA was unable to 
alter Lhb mRNA levels, however, E2 significantly decreased levels of Lhb mRNA in both 
males (Figure 10E) and females (Figure 10F) at PND7. We next examined the five-
week old mice. For Lhb mRNA levels, there was no effect of BPA or E2 exposure in 
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males (Figure 10G). Females similarly did not demonstrate any difference in Lhb mRNA 
with BPA exposure, however, there was suppression of Lhb mRNA with E2 exposure 
(Figure 10H). Despite seeing effects on the gonadotrope lineage due to E2 treatment, 
there were no effects on timing of puberty, as assessed by preputial separation, or 
vaginal opening with E2 or BPA treatment (Table 5). 
Experiment 2: Low levels of BPA exposure decreased Pit1 mRNA in males only, without 
altering hormone transcript levels: 
 PIT1 is a transcription factor found exclusively in the pituitary gland and is 
important in the development of lactotropes, somatotropes, and thyrotropes, and 
expression of their respective hormones. The lowest doses of BPA, BPA0.05 and 
BPA0.5, decreased levels of Pit1 mRNA in males, however, the higher dose of BPA, 
BPA50, and E2 had no effect on Pit1 mRNA during this time period (Figure 11A). 
Females, on the other hand, did not show an effect on Pit1 mRNA with any dose of BPA 
or E2 (Figure 11B). To determine if the decrease in Pit1 mRNA in males would 
correspond with a decrease in protein, western blot analysis was done. No significant 
change in PIT1 protein was seen with any treatment group in males at PND7 (Figure 
11C). Finally, to determine if there was any effect of decreased Pit1 mRNA levels, 
transcription levels of the hormones regulated by PIT1 were analyzed. BPA had no 
effect on Prl mRNA, however, E2 significantly increased Prl mRNA in males (Figure 
11D) and females (Figure 11E). Neither BPA nor E2 had any effect on Gh mRNA levels 
in males (Figure 11F) or females (Figure 11G). BPA and E2 also had no effect on Tshb 
mRNA levels in males (Figure 11H) or females (Figure 11I). Finally, to see if the 
decrease in Pit1 mRNA seen in males at PND7 would be present after removal of BPA, 
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we examined the five-week old mice. There was no effect of exposure to BPA or E2 at 
five weeks in males (Figure 11J) or females (Figure 11K). 
Experiment 2: BPA decreased Pomc mRNA in a dose and sex specific manner:  
The last lineage examined was the TPIT lineage, which includes the corticotrope 
and melanotrope cells. At PND7 there was no effect of BPA or E2 exposure on Tpit 
mRNA levels in males (Figure 12A) or females (Figure 12B). However, the middle dose 
of BPA, BPA0.5, and E2 both decreased Pomc mRNA in males, however, the lowest 
dose of BPA, BPA0.05 and the highest dose, BPA50 showed no change in Pomc 
mRNA (Figure 12C). In females, Pomc mRNA was reduced with exposure to BPA0.5, 
BPA50, and E2 with only BPA0.05 unable to alter Pomc mRNA levels (Figure 12D). 
Next, intra-pituitary POMC protein levels were examined by western blot analysis in 
both males (Figure 12E) and females (Figure 12F) and no change in protein levels were 
detected in either sex. Next, Pomc mRNA levels were assessed at five weeks. No 
significant changes in Pomc mRNA were observed in males (Figure 12G). BPA0.5 
treated females, however, had lower Pomc mRNA compared to control females (Figure 
12H).  
Discussion: 
We demonstrate that there are critical windows of development in which the 
pituitary is sensitive to BPA exposure and that there are differential effects based on 
age and sex. Embryonic exposure to BPA increased pituitary proliferation and 
gonadotrope number in a sex-specific manner (Brannick et al. 2012). We now 
demonstrate this effect was not present at PND4, five days after removal of BPA. 
Exposure to BPA during the neonatal period did not affect proliferation and also had 
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little effect on gonadotropes. However, we did see a decrease in Pit1 mRNA with lower 
doses of BPA in males and sex specific decreases in Pomc mRNA with exposure to 
BPA and E2. At five weeks, after the first postnatal growth phase of the pituitary has 
ended, a similar reduction of Pomc mRNA with exposure to BPA0.5 and the 
appearance of a decrease in Nr5a1 mRNA with exposure to BPA0.05 in females were 
shown. Therefore, these findings highlight that the pituitary is dynamically affected by 
BPA exposure in a sex specific manner and emphasize the need for examining different 
periods of exposure and times after exposure. 
Previously, our lab has shown that embryonic exposure to BPA led to an 
increase in progenitor proliferation and differentiation to the gonadotrope lineage at 
PND0 in females (Brannick et al. 2012). Additionally, we now find increased apoptosis 
at PND0 with BPA exposure. There is precedence for this developmental effect as BPA 
has been shown to simultaneously increase proliferation and apoptosis in 
spermatogenic cells (Xie et al. 2016). Whether both proliferation and apoptosis are 
directly increased by BPA exposure or if one is a mechanism enacted by the pituitary to 
counteract the effects of the other is unknown. The pituitary has been shown to be able 
to minimize the effects of exposure to compounds in other scenarios. In adults 
chronically exposed to estrogen, senescence mechanisms are activated to decrease 
the proliferation rate (Sabatino et al. 2015), thus limiting tumor growth. Interestingly, 
when BPA exposure is stopped before birth, proliferation and gonadotrope number at 
PND4 is not altered. This potentially suggests that the pituitary can adjust cell dynamics 
during the postnatal developmental period if allowed to be removed from BPA.  
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The impact of neonatal exposure to BPA was not similar to the effects observed 
with embryonic dosing. Embryonic BPA exposure demonstrated increased proliferation 
and Lhb mRNA regulation in female offspring (Brannick et al. 2012). However, neonatal 
exposure demonstrated no change in either parameter in either sex. A higher 
concentration of 50mg/kg/day BPA and direct stimulation of the neonatal pituitary also 
did not regulate Lhb and Fshb mRNA (Eckstrum et al. 2016), demonstrating effectively 
that in the neonatal pituitary, gonadotropes are less affected by BPA exposure than 
during embryogenesis. There could be many reasons the neonatal period did not 
respond to BPA in the same way. Pituitary cell composition and receptor levels vary 
over the developmental period (Yoshimura et al., 1970; Carbajo-Perez and Watanabe, 
1990; Pasqualini et al., 1999), which could alter the precise cellular dynamics leading to 
these changes. Additionally, the functionality of the hypothalamic-pituitary-gonadal 
(HPG) axis during these two periods may also play a role. Development of the HPG axis 
begins prior to birth (Pointis and Mahoudeau, 1976) and is of critical importance to the 
pituitary as hypogonadal (hpg) mice lacking GnRH and kisspeptin receptor, GPR54, 
knockout mice have lower serum gonadotropin levels at birth (Poling & Kauffman 2012). 
However, after birth the pituitary does not respond to GnRH with increased LH release 
until two weeks of age, despite a high frequency of GnRH stimulation in the first week of 
life (Glanowska et al. 2014). This suggests that the pituitary is hypo-responsive to 
stimuli during the neonatal period, compared to the embryo or the adult. Perhaps, late 
during the embryonic period, the HPG axis and regulation of proliferation and Lhb 
mRNA is active, but after birth the responsiveness of the pituitary to GnRH and 
proliferation signals is decreased, preventing Lhb mRNA and proliferation to be 
69 
 
disrupted by BPA during the neonatal period. Another possibility to explain the 
differences between the embryonic and neonatal exposure results is that CD1 mice, 
used in the neonatal study, and FVB/BL6 mice, used in the embryonic study, have 
different sensitivity to BPA exposure. It is possible that FVB/BL6 mice have a more 
sensitive gonadotrope lineage, whereas the CD1 mice have greater sensitivity in the 
PIT1 and TPIT lineages. An example of differential effects due to mouse strain occurs in 
the uterus where CD1 mice exposed to BPA did not develop pyometra, whereas 
C57BL/6 mice exposed to the same concentrations of BPA did (Kendziorski et al. 2012). 
However, there is also evidence to support that mouse strain does not affect antral 
follicles differently with respect to growth and steroidogenesis (Peretz et al. 2013). 
Despite an absence of similar changes in the neonatal and embryonic period, 
effects were observed that were specific to neonatal exposure. The lowest doses of 
BPA, within the range of human exposure, decreased Pit1 mRNA, in males. To the best 
of our knowledge, BPA has not been previously shown to affect Pit1 transcription. This 
could be a non-estrogenic action because the same effect was not seen with E2. 
However, E2 has been shown to increase Pit1 mRNA in cell lines and somatotrope 
specific ER alpha knockout mice in adults (Avtanski et al. 2014). It is possible regulation 
of Pit1 mRNA by E2 was not seen here because of the neonatal timing. BPA has been 
shown to bind different receptors including the androgen receptor, estrogen-related 
receptor, thyroid hormone receptor, peroxisome proliferator-activated receptor, aryl 
hydrocarbon receptor, and glucocorticoid receptor (reviewed in Acconcia et al., 2015; 
Prasanth et al., 2010). Therefore, it is possible that BPA may be acting through one of 
these receptors to reduce Pit1 mRNA levels. Despite the decrease in Pit1 mRNA with 
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low doses of BPA in males, we did not see any effect on transcript levels of Prl, Gh, or 
Tshb. Furthermore, we did not see any change in protein levels of PIT1, which supports 
the lack of changes in transcription of genes regulated by PIT1. These data suggest the 
pituitary may adapt to maintain consistent levels of PIT1 in the presence of BPA 
exposure.  
Neonatal BPA exposure also had striking effects on the TPIT lineage that were 
not seen following embryonic dosing. We observed a decrease in Pomc mRNA in the 
E2, BPA0.5, and BPA50 exposed females and with only BPA0.5 and E2 exposure in 
males, independent of Tpit mRNA changes. E2 exposure in the adult has been shown 
to reduce Pomc mRNA in the pituitary, which also leads to decreased plasma ACTH 
and corticosterone levels when stressed (Redei et al. 1994). Seeing the same 
suppression of Pomc in the neonate suggests that the mechanism by which this 
inhibition takes place is established early on. However, the precise mechanism is 
unclear. Interestingly, BPA50 exposed males did not show a decrease in Pomc mRNA. 
This represents a crucial sex difference in Pomc mRNA regulation with varying amount 
of exposure, and potentially a non-monotonic dose response in males. Despite this, we 
did not see a decrease in intra-pituitary POMC protein expression. There could be a 
variety of explanations such as increased translation to compensate for decreased 
transcription. Alternatively, it could be that hormone release is also affected, and intra-
pituitary POMC levels are kept very consistent. Other studies in rats have demonstrated 
the ability of BPA to regulate Pomc mRNA levels and blood ACTH levels in males 
compared to females in response to stress (F. Chen et al. 2014; Panagiotidou et al. 
2014), emphasizing the importance of sex as a variable in research on the HPA axis. 
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Of the parameters examined, there were few effects of BPA exposure at five 
weeks following neonatal dosing. There was a decrease in Nr5a1 in BPA0.05 treated 
female pituitaries at five weeks, however, there was no corresponding decrease in Lhb. 
Additionally, changes in Pit1 at PND7 were not seen at five weeks. However, there was 
a suppression of Pomc in BPA0.5 treated females at five weeks, suggesting the 
possibility of lasting effects on the stress axis. Despite the minimal effects of BPA on the 
five-week old pituitary it is possible that changes may be present at different timepoints. 
It is also important to note that exposure to BPA is constant over the life span of a 
person so one would likely never be removed from BPA. Despite the relative lack of 
changes due to BPA, E2 exposure affected the reproductive axis of five-week females 
leading to lower Nr5a1 and Lhb levels as well as persistent estrus. Therefore, neonatal 
E2 exposure may have permanently altered the HPG axis, which could impact fertility in 
females.  
Overall, we saw contrary effects of BPA exposure in the embryonic versus the 
neonatal period. This may be demonstrating that the critical window for proliferation and 
gonadotrope regulation is embryonic, whereas, the critical window for corticotrope 
regulation is neonatal. After removal of BPA minimal effects were seen, potentially 
demonstrating the plasticity of the pituitary in being able to regulate itself to maintain 
proper cell number and hormonal signaling. A commonality in both the embryonic and 
neonatal periods is the existence of sex specific effects, which may hint at either 
baseline differences in male and female pituitaries or differences in hormone signaling 
that would be worth further exploration. 
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Figures and Tables 
 
 
 
Figure 8: Female pituitary recovered from embryonic BPA exposure, likely due to 
increased cell death. Proliferation was assessed by mKi67 immunostaining in female 
pups exposed to control (A), 0.5 μg/kg/day BPA (B), or 50 μg/kg/day BPA (C), 
demonstrating no difference in proliferating cells in the cleft at PND4. Gonadotrope cell 
number was assessed by LHβ cell counts in control (D), 0.5 μg/kg/day BPA (E), and 50 
μg/kg/day BPA (F), demonstrating no difference between any treatment group at PND4. 
Cell death was assessed by TUNEL stain at PND0 in control (G), 0.5 μg/kg/day BPA 
(H), 50 μg/kg/day BPA (I) arrows denote positive cells. Quantification of positive TUNEL 
stain at PND0 showed increased cell death with 0.5 μg/kg/day BPA and 50 μg/kg/day 
BPA (J). Quantification of positive TUNEL stain at PND4 showed no significant 
differences in TUNEL stain (K). (#) = p value ≤ 0.05. Line=50 μm, n=3 
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Table 3: PND7 wet weights and measurements. Body weight, wet weights of testes, 
ovaries, uteri, and liver were compared as a percentage of body weight, and ano-genital 
distance (AGD) were compared as mm/gram body weight (gBW). N=6 for males and 
females. (*) = p value ≤ 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 WEIGHT(g) TESTES 
(%BW) 
OVARIES 
(%BW) 
UTERI 
(%BW) 
LIVER 
(%BW) 
MALE 
AGD 
(mm/gBW) 
FEMALE 
AGD 
(mm/gBW) 
CONTROL 4.568 0.175 0.049 0.093 3.118 1.142 0.913 
BPA0.05 4.105 0.177 0.038* 0.094 3.012 1.161 0.823 
BPA0.5 4.432 0.170 0.043 0.096 3.137 1.095 0.829 
BPA50 4.545 0.179 0.044 0.104 3.201 1.203 0.816 
E2 4.618 0.183 0.057 0.195* 3.163 1.146 0.825 
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Table 4: Five week wet weights and measurements. Body weight, wet weights of testes, ovaries, uteri, and liver were 
compared as a percentage of body weight, and ano-genital distance (AGD) were compared as mm/gram body weight 
(gBW). N=3-6 for males and females. 
 
 
 
 
 
 
 
 
 
 
 
  
 WEIGHT 
MALE 
(g) 
WEIGHT 
FEMALE 
(g) 
TESTES 
(%BW) 
OVARIES 
(%BW) 
UTERI 
(%BW) 
LIVER 
(%BW) 
MALE 
AGD 
(mm/gBW) 
FEMALE 
AGD 
(mm/gBW) 
CONTROL 27.446 23.517 0.499 0.092 0.792 6.470 0.47 0.28 
BPA0.05 26.950 22.350 0.506 0.112 0.937 6.570 0.50 0.29 
BPA0.5 27.813 23.083 0.509 0.095 0.689 5.373 0.49 0.30 
BPA50 29.743 23.136 0.505 0.110 0.760 6.309 0.51 0.31 
E2 27.111 24.675 0.573 0.080 0.598 6.842 0.48 0.28 
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Figure 9: Proliferation was not changed by neonatal exposure to BPA or E2. 
Proliferation was measured by Mki67 mRNA levels in males (A) and females (B) at 
PND7, demonstrating no significant change in proliferation. At five weeks, no significant 
change in proliferation in males (C) or females (D) was observed as well. N=3-6 for 
each sex. Circles represent individual animals and average is represented by a line. 
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Figure 10: Gonadotrope markers were unchanged due to neonatal BPA exposure, 
despite regulation by E2. Gonadotrope marker Nr5a1 mRNA was measured in males 
(A) and females at PND7 (B), with no response to BPA. At five weeks, there was no 
effect of BPA or E2 in males (C), but there was suppression of Nr5a1 mRNA in females 
with exposure to BPA0.05 and E2 (D). Lhb mRNA was decreased by E2 in males (E) 
and females (F) at PND7 but was unchanged by BPA (E). At five weeks, Lhb was 
unaltered by any treatment group in males (G). In females, at five weeks, E2 caused 
significant repression of Lhb mRNA (H). For PND7 n=5-6. For five weeks n=3-6. Circles 
represent individual animals and average is represented by a line. (#) = p value ≤ 0.05. 
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 Preputial Separation (day) Vaginal Opening (day) 
CONTROL 23.695 22.514 
BPA0.05 23.700 23.533 
BPA0.5 24.222 23.167 
BPA50 24.104 23.422 
E2 25.780 21.667 
 
Table 5: Puberty measurements. Day of preputial separation and vaginal opening were 
monitored and averaged for males (n=3-5) and females (n=4-6).  
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Figure 11: BPA suppressed Pit1 mRNA at low doses in males but did not alter 
transcription of PIT1 lineage hormones. Pit1 mRNA was decreased at PND7 with 0.05 
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Figure 11 continued: and 0.5 μg/kg/day BPA in males (A), but not females (B). 
However, PIT1 protein was not changed by BPA or E2 in males by western blot analysis 
(C).  Prl mRNA was not altered by BPA but was increased with E2 in males (D) and 
females (E). No difference in Gh mRNA with any treatment in males (F) or females (G), 
and no difference in Tshb mRNA with BPA or E2 exposure in males (H) or females (I) 
was detected. Pit1 mRNA at five weeks was not changed in males (J) or females (K). 
For qPCR, n=3-6 and for PND7 western blot n=3. Circles represent individual animals 
and average is represented by a line. (#) = p value ≤ 0.05. 
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Figure 12: Pomc mRNA was suppressed by BPA and E2 neonatal exposure. 
Tpit mRNA was unchanged by BPA or E2 at PND7 in males (A) and females (B). Pomc 
mRNA was decreased with 0.5 μg/kg/day BPA and E2 at PND7 in males (C) and 
decreased with 0.5 μg/kg/day BPA, 50 μg/kg/day BPA and E2 in females (D). POMC 
protein was unchanged by BPA in males (E) and females (F). Pomc mRNA was not 
different with treatment at five weeks in males (G), however, there was a persistent 
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Figure 12 continued: decrease in females treated with 0.5 μg/kg/day BPA (H). For 
qPCR, n=3-6 and for PND7 western blot n=3. Circles represent individual animals and 
average of combined sexes is represented by a line. (#) = p value ≤ 0.05. 
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Chapter 4: Estrogen receptor mediated down-regulation of gonadotrope specific 
genes in the neonatal pituitary 
 
 
Abstract:                                               
 In the pituitary, estradiol is involved in the down regulation of several genes 
expressed in gonadotrope cells including Lhb, Fshb, and Icam5. However, very little is 
known about the mechanism by which this happens including which specific estrogen 
receptor or receptors are important. Estradiol signals through multiple receptor 
pathways in order to alter transcription of genes. The three estrogen receptors are 
estrogen receptor alpha (ESR1), estrogen receptor beta (ESR2), and the G-protein 
coupled estrogen receptor (GPER). Activation of these receptors can lead to either up 
regulation or down regulation of specific gene expression. To address the question of 
how Lhb, Fshb, and Icam5 are regulated, we treated cultured ex vivo pituitaries with 
ESR1 selective agonist propyl pyrazole triol (PPT), ESR2 selective agonist 
diarylpropionitrile (DPN), ESR1 and ESR2 antagonist ICI 182,780 (ICI), and an estrogen 
dendrimer (ED) conjugate, which selectively activates membrane signaling. We found 
that all the genes decreased by estradiol seemed to be regulated slightly differently. Lhb 
was suppressed by combined ESR1 and ESR2 signaling in females, but not regulated 
in males by E2 or selective agonists. Fshb was decreased by E2 in females and ICI in 
males, however, specific agonists and combinations of agonists were unable to 
recapitulate this effect and in fact were able to increase Fshb levels with combined 
ESR1 and ESR2 in males and combined ESR1, ESR2, and membrane signaling in 
males and females. Finally, although Icam5 was slightly decreased by PPT in females, 
nuclear and membrane signaling components were necessary for full suppression in 
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males. The vast variety of pathways estradiol can use to elicit changes in a cell 
demonstrates the complexity of estrogen signaling and stresses the importance of 
analyzing the various mechanisms by which these genes are regulated. 
Introduction:  
Estrogen is a steroid hormone that is critical in the proper functioning of the 
hypothalamic pituitary gonadal (HPG) axis. If estrogen signaling is enhanced, 
diminished or altered in any way, this can lead to the development of several diseases 
including tumor formation and reproductive dysfunction (Wendell et al. 2006; Mary C. 
Gieske et al. 2008; Leret et al. 1994). These endocrine related health concerns can 
potentially be due to the effects of estrogen on the pituitary gland. In the HPG axis, 
gonadotropin releasing hormone (GnRH) from the hypothalamus stimulates the release 
of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the 
gonadotrope cells of the anterior pituitary, which then stimulates the testes or ovaries to 
make sex steroids, such as testosterone or estradiol, which then can feed back on the 
axis to decrease GnRH, LH, and FSH.  In the neonatal period, sex steroids also 
establish critical sex differences. The neonatal testosterone surge is responsible for 
masculinization or defeminization of several areas of the brain, however, interestingly it 
is not testosterone itself that leads to these changes, it is estradiol, through the 
conversion of testosterone to estradiol via aromatase (McCarthy 2008). One key sex 
difference during the neonatal period is that serum levels of LH and FSH are lower in 
males than in females after birth (Poling & Kauffman 2012). Recently, we have 
discovered that the neonatal pituitary also has sex differences in gene expression of 
Lhb, Fshb, and Icam5. Interestingly, these sex differences are exclusively found in the 
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gonadotrope cells, which release LH and FSH (Eckstrum et al. 2016). Additionally, 
expression of all these genes can be suppressed by E2 in vivo, yet it still is not known 
which receptor E2 signals through to have these effects, because there are many 
receptors estrogen can signal through. 
In order for estrogen to have these effects on the pituitary, it must express the 
proper estrogen receptors of which there are three expressed in most tissues: estrogen 
receptor alpha (ESR1), estrogen receptor beta (ESR2), and the G protein-coupled 
estrogen receptor (GPER). The pituitary possess all these estrogen receptors 
(Nishihara et al. 2000; Ogasawara et al. 2009; Hazell et al. 2009), however, the specific 
cells in the pituitary that possess ESR1 is a bit unclear. In the chick embryo, the majority 
of ESR1 cells colocalized with gonadotrope cells. However, some expression was also 
found in thyrotropes and lactotropes, whereas corticotropes and somatotropes were 
ESR1 negative (Liu Sheng Cui 2005). Many cells in the adult pituitary have been shown 
to express ESR1 and ESR2, but expression of ESR1 is generally thought to be higher 
than ESR2 (Mitchner et al. 1998). In the pituitary of an ovariectomized rat, mRNA 
expression of ESR1 and ESR2 is detectible in lactotropes, corticotropes, gonadotropes, 
melanotropes, and folliculo-stellate cells (Mitchner et al. 1998), however, not every cell 
expressed ESR1 or ESR2. In another study that examined protein levels during 
proestrus, ESR1 was found in lactotropes, thyrotropes, gonadotropes, and 
somatotropes, but not corticotropes (González et al. 2008). Therefore, it seems from the 
embryonic and adult studies that ERs are expressed in almost every cell type, however, 
few studies have looked specifically at the neonatal pituitary. In the neonatal rat, nuclear 
staining of ESR1 is visible in the anterior lobe and cytoplasmic staining is present in the 
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intermediate lobe (Pasqualini et al. 1999). GPER expression in the pituitary is less well 
established. About half of the GPER positive cells co-localize with LH and about 30% of 
LH positive cells express GPER in the adult bovine pituitary (Rudolf & Kadokawa 2013), 
therefore, GPER must be expressed in other cells in the pituitary in addition to 
gonadotrope cells. Therefore, studies seem to suggest that all three ERs are expressed 
in gonadotrope cells. 
Each of the estrogen receptors have different ways of causing changes within a 
cell. Classical estrogen signaling occurs when estrogen binds to ESR1 or ESR2. This 
activates the receptor and leads to homodimerization of the receptor, which will then 
bind to estrogen-response-elements (EREs) in the regulatory regions of target genes in 
the nucleus. Once bound, a variety of cofactor proteins are recruited that help to 
stabilize the transcription preinitiation complex. Depending on the contexts, the effect of 
binding can be either to activate or inhibit transcription (Hall et al. 2001). Alternatively, 
genomic estrogen signaling can occur in the absence of EREs. In this scenario, ESR1 
or ESR2 binds to other transcription factors, such as Fos and Jun at AP-1 binding sites 
for example, and again recruits cofactor proteins that can either activate or inhibit gene 
transcription (Kushner et al. 2000). Finally, there are also non-genomic membrane-
mediated effects of estrogen signaling. First ESR1 and ESR2, which can both be found 
in membrane fractionations (Razandi et al. 1999), can associate with membrane 
receptors, such as G proteins, leading to the activation of numerous kinase signaling 
cascades (Levin 2009). Membrane signaling can also occur through G protein-coupled 
estrogen receptor (GPER), a 7-transmembrane protein receptor found in the plasma or 
endoplasmic reticulum membrane. Activation of GPER stimulates many intracellular 
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signaling pathways including adenylate cyclase, ERK/MAPK, and PI3K/AKT pathways 
(Filardo & Thomas 2012; Xie et al. 2017). Membrane signaling can have several rapid 
effects through the actions of the kinase signaling cascades, such as the E2 stimulated 
release of prolactin (Christian & Morris 2002). Membrane signaling can also eventually 
lead to transcriptional changes. For example, activation of membrane ERs can lead to 
phosphorylation of CREB, through MAPK, which can then regulate gene expression 
through interaction on CREB response elements (CREs) (Micevych & Mermelstein 
2008). Therefore, there are several pathways and several factors involved in the ability 
of estrogen to regulate the cell and importantly, gene transcription. Because there are 
so many pathways by which estrogen can cause changes in a cell, it can be difficult to 
determine the precise mechanism by which genes are regulated. 
We have previously found that E2 suppresses expression of key genes in the 
gonadotrope cells including Lhb, Fshb, and Icam5 in the neonatal pituitary (Eckstrum, 
Weis, Baur, Yoshihara, & Raetzman, 2016). In the current study, to determine the 
precise mechanism by which E2 regulates these genes, a variety of compounds were 
used to selectively activate or inhibit the different estrogen receptors. Propyl pyrazole 
triol (PPT) is an ESR1 selective agonist and it has a 410-fold preference for ESR1 over 
ESR2 (Stauffer et al. 2000). Diarylpropionitrile (DPN) is an ESR2 selective agonist and 
has a 70-fold higher binding preference for ESR2 than ESR1 (Meyers et al. 2001). To 
activate membrane estrogen signaling, estrogen dendrimer conjugates were used, 
which are large poly(amido)amine dendrimer macromolecules that are conjugated to 
multiple estrogen molecules. Due to the charge and size of the estrogen dendrimers, 
they cannot pass into the nucleus. Binding affinity assays demonstrate that the 
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dendrimer does not reduce the ability of the estrogen to interact with ER (Harrington et 
al. 2006). Additionally, ICI 182,780, a pure estrogen receptor antagonist, meaning it 
blocks the actions of ESR1 and ESR2 and can bind these receptors with the same 
affinity as estradiol (Wade et al. 1993), will determine if E2 signals through ESR1 or 
ESR2 to regulate transcription of our genes. ICI works by disrupting shuttling of ESR1 
and ESR2 between the nucleus and cytoplasm and decreasing cellular levels of ESR1 
and ESR2 (Dauvois et al. 1993; Howell et al. 2000).  
We hypothesized that Lhb, Fshb, and Icam5 would be regulated through one or 
multiple estrogen receptors in the neonatal pituitary. To test this hypothesis, neonatal 
pituitaries were treated with selective agonists and antagonists either alone, or in 
combination with other compounds. We found that each of the genes downregulated by 
estradiol were regulated slightly differently. Lhb seems to be regulated through ESR1 
and ESR2 in females only, Fshb seems to be regulated by multiple receptors in 
opposing ways. Lastly, Icam5 appears to be regulated by both nuclear and membrane 
signaling. The fact that none of the genes downregulated by E2 in the neonatal pituitary 
are regulated in the same way highlights the diversity of possible signaling pathways 
through which estrogen can alter transcription and shows the importance of finding the 
specific mechanisms by which these genes are regulated. 
Materials and methods 
Mice 
CD-1 mice were bred in house, kept in plastic cages containing corn cob bedding 
material, and fed Teklad 8664 rodent chow (Envigo) and water ad libidum. Mice were 
collected at PND0, PND4, PND9, and six weeks (adult). Females were collected in 
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diestrus for Esr1 and Esr2 analysis (n=6-11). Mice were collected at PND1 for ex vivo 
pituitary cultures. Sex was confirmed by visual inspection and SRY genotyping as 
previously described (Eckstrum et al. 2016). The University of Illinois Urbana-
Champaign Institutional Animal Care and Use Committee approved all procedures. 
Ex vivo pituitary cultures 
PND1 pituitaries were cultured overnight on Millicell CM membranes (Millipore) 
as previously described (Eckstrum et al. 2016). The next day media were replaced with 
media containing control (ethanol 0.2%), propyl pyrazole triol (PPT) (10-8M) purity > 
99% (Tocris), diarylpropionitrile (DPN) (10-8M) purity > 99% (Tocris), estrogen 
dendrimer conjugate (10-9M), dendrimer conjugate (dendrimer control) (10-9M) (a 
generous gift from Dr. John Katzenellenbogen, University of Illinois Champaign-
Urbana), estradiol (E2) (10-8M)  purity > 99% (Tocris), or ICI 182,780 (10-5M or 10-6M) 
purity > 99% (Tocris) or a combination of these compounds for 48 hours before 
collection (n=6-13). 
Quantitative RT-PCR 
Cultured pituitaries were rinsed with PBS before being collected and both 
cultured and in vivo pituitaries were processed as previously described (Nantie et al. 
2014). Actb and Cckar primers were previously used in our lab (Weis & Raetzman 
2016), as were Lhb, Fshb, Prl (Brannick et al. 2012), and Icam5 (Eckstrum et al. 2016). 
Esr1 primers were forward 5’ to 3’: AATTCTGACAATCGACGCCAG and reverse 5’ to 
3’: GTGCTTCAACATTCTCCCTCCTC. Esr2 primers were forward 5’ to 3’: 
GGATGAGGGGAAGTGCGTGGAAGG and reverse 5’ to 3’: 
AGTTTTAACTCACGGAACCGTGCCG. Pmaip1 primers were forward 5’ to 3’: 
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GCCAATCTGTTTTAGGGTGA and reverse 5’ to 3’: CAGAACAGGCAACATCCGTT. 
Data were analyzed using the standard comparative ΔCT value method as previously 
described (Goldberg et al. 2011). The error bars in the figures represent the SEM of the 
relative fold-change for each group. 
Statistical Analysis 
Statistical significant was determined using a one-way ANOVA in excel for ICI 
experiment followed by a two-tailed Tukey’s HSD test or only the Tukey’s HSD test in 
Microsoft Excel. P values less than or equal to 0.05 were considered statistically 
significant. Outliers were eliminated as determined by the Grubb’s test. 
Results:  
Esr1 mRNA increases over the postnatal period while Esr2 mRNA decreases 
First, to determine dynamics of estrogen receptor expression in the neonatal 
pituitary compared to an adult, we examined Esr1 and Esr2 mRNA expression from 
birth to adult. Over the course of the postnatal period, levels of Esr1 increased over time 
in males and females compared to PND0 (Figure 13A), whereas levels of Esr2 
decreased over time in males and females (Figure 13B). Thus, higher expression of 
Esr2 during the neonatal period than in the adult may suggest a greater role for ESR2 
during the neonatal period. Additionally, at birth, there was no difference in expression 
of Esr1 or Esr2 between males and females, suggesting that when pituitaries are taken 
out and treated in culture with selective agonists, receptor levels of Esr1 and Esr2 may 
be similar between the sexes. 
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Confirmation of selective activation of estrogen receptors with PPT, DPN and ED 
To determine the roles the different estrogen receptors play in the regulation of 
Lhb, Fshb, and Icam5, we first confirmed the doses for the selective agonists. A dose 
response curve was performed for the ESR1 selective agonist propyl pyrazole triol 
(PPT) to determine a minimal dose of PPT that was sufficient to induce expression of 
ESR1 regulated gene Cckar (Kim et al. 2007). All doses of PPT from 10-8M to 10-5M 
were sufficient to induce expression Cckar, therefore, PPT 10-8M was used for further 
studies (Figure 14A). The ESR2 selective agonist, diarylpropionitrile (DPN) increased 
Cckar from 10-8M to 10-5M, but not at 10-9M, therefore, DPN 10-9M was used for further 
studies (Figure 14B). Finally, the estrogen dendrimer (ED (10-9M)) regulated expression 
of a known membrane estrogen regulated gene phornol-12-myristate-13-acetate-
induced protein 1 (Pmaip1) in males only (Figure 14C) (Madak-Erdogan et al. 2008). 
Nevertheless, this shows that this dose of ED was sufficient to activate membrane 
signaling. The estrogen dendrimer only slightly increased expression of nuclear 
signaling regulated Cckar mRNA compared to that of E2 exposure (Figure 14D). 
Therefore, this concentration of ED was chosen to best balance activation of membrane 
signaling while minimizing nuclear signaling.  
Lhb mRNA is decreased by ESR1 and ESR2 combined signaling in females 
Whole animal E2 exposure in the neonatal period decreased pituitary Lhb mRNA 
in both males and females; however, pituitary E2 treatment in vitro decreased Lhb 
mRNA in females only (Eckstrum et al. 2016). The estrogen receptor that leads to a 
decrease in Lhb is unknown at this age. Co-treatment of ICI and E2 reversed the 
decrease in Lhb in female pituitaries and ICI alone had no significant effect in either sex 
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(Figure 15A), suggesting that ESR1 or ESR2 is important in regulation of Lhb mRNA. 
However, PPT (Figure 15B), DPN (Figure 15C), and the ED (Figure 15D) were all 
insufficient to decrease Lhb on their own, suggesting maybe more than one receptor is 
necessary for regulation. Combined treatment of PPT and DPN decreased Lhb in 
females similar to the decrease with E2 (Figure 15E) and there was no increased effect 
when the ED was also added to PPT and DPN (Figure 15F), suggesting Lhb is 
regulated by a combination of ESR1 and ESR2 signaling. 
Fshb mRNA is regulated by multiple signaling pathways in opposing ways 
E2 exposure in the neonatal period in vivo decreased Fshb mRNA in both males 
and females and in vitro E2 treatment decreased Fshb mRNA in females only 
(Eckstrum et al. 2016). Here, we add that co-treatment of ICI and E2 was able to 
reverse the decrease in Fshb mRNA seen with E2 exposure in females, however, ICI 
alone was also able to decrease Fshb mRNA in males (Figure 16A). Co-treatment of E2 
+ICI suggests either ESR1 or ESR2 is important in down regulation of Fshb in females, 
however, the effects of ICI in males also suggest other signaling pathways are 
important. Similarly, to Lhb transcription, PPT (Figure 16B), DPN (Figure 16C), and the 
ED (Figure 16D) were all unable to regulate Fshb alone, again suggesting more than 
one receptor may be required. Surprisingly, co-treatment of PPT+DPN increased Fshb 
in males and females (Figure 16E). Addition of the ED did not change the direction of 
Fshb regulation, and the PPT+DPN+ED treatment increased Fshb mRNA in males and 
females (Figure 16F). Taken together, these data show that upregulation of Fshb mRNA 
in vitro is through ESR1 and ESR2, but the mechanism by which E2 decreases Fshb 
remains elusive. 
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E2 decreases Icam5 through a combination of membrane and nuclear signaling 
pathways 
Previously, we had demonstrated that E2 decreases Icam5 mRNA in vivo and 
that this decrease can occur directly at the level of the pituitary in males and females. 
This decrease is completely blocked by ICI and ICI alone has no effect (Eckstrum et al. 
2016). This suggests either ESR1, ESR2, or both are important in regulation of Icam5. 
PPT slightly decreased levels of Icam5 (Figure 17A) in females, but not in males; 
however, the decrease was not as great as it was with E2 treatment, which was about a 
35% decrease (Eckstrum et al. 2016). These data suggest that another receptor may 
also be important for regulation of gene expression. Neither DPN (Figure 17B) nor the 
ED (Figure 17C) could regulate Icam5 alone. Additionally, PPT+DPN had no effect on 
Icam5 (Figure 17D). However, co-treatment of PPT, DPN, and the ED, did decrease 
Icam5 levels in both males and females (Figure 17E), suggesting both membrane and 
nuclear signaling components may be necessary for Icam5 regulation. 
Discussion 
Estrogen can signal through several receptor pathways and intermediate 
proteins. This diversity allows the main estrogen, E2, to have a wide array of effects in 
many different tissues. In the neonatal pituitary, we saw that E2 could decrease 
expression of key genes in the gonadotrope cells, Lhb, Fshb, and Icam5, potentially 
leading to the establishment of sex differences in expression of these genes. However, 
the mechanism by which these genes are regulated is not well established, especially in 
the neonatal pituitary. The first step in determining the mechanism by which these 
genes are regulated was to determine the precise estrogen receptor important in gene 
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regulation. Therefore, we treated pituitaries with a variety of selective agonists and 
antagonist in hopes of finding the critical receptor. Table 6 provides a summary of the 
effects of each of the selective agonists in males and females. Interestingly, we found 
Lhb to be regulated by ESR1 and ESR2 in females only. Fshb may be differentially 
regulated by different estrogen receptors in a complicated system involving levels of 
activation of each receptor. Finally, Icam5 required components of nuclear and 
membrane signal to exhibit repression in both males and females. Therefore, the 
signaling mechanisms by which E2 decreases gene expression in the neonatal pituitary 
appear to involve multiple receptors and mechanisms. 
Direct stimulation of the neonatal pituitary with E2 decreased Lhb mRNA only in 
females. The combination of PPT and DPN reduced levels of Lhb in females similarly to 
E2, suggesting that both ESR1 and ESR2 play a role in this unique suppression during 
the neonatal period at the level of the pituitary in females. It could be that both ESR1 
and ESR2 are important because in the neonatal period levels of Esr1 are lower than 
they are in the adult, whereas Esr2 levels are higher so both end up being important. It 
is interesting that when PPT, DPN, and the ED were all combined there was no longer a 
decrease in Lhb in females. A possible explanation for this is that membrane signaling 
caused by the ED may interfere with Lhb transcriptional regulation. Other studies have 
demonstrated a different time course of action for E2 and the ED (Alyea et al. 2008), 
which may also explain the results.  
This study and a previous study examining treatment of a synthetic estrogen, 
diethylstilbestrol (DES), on neonatal pituitaries in culture show a decrease in Lhb levels, 
(Ishikawa et al. 2014). However, in the adult female, Lhb mRNA appears to be primarily 
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regulated by ESR1, but not directly at the pituitary. E2 exposure in adult ESR1 KO mice 
does not decrease Lhb mRNA in vivo and in cultured pituitary cells and E2 does not 
decrease Lhb after 48hrs (Lindzey et al. 2006). In fact, in 6 hr cultured hemipituitaries of 
ovariectomized rats, E2 actually increased Lhb transcription through direct binding to an 
ERE located in the Lhb promoter (Margaret A. Shupnik et al. 1989; M A Shupnik et al. 
1989). However, conflicting results in pituitary specific ESR1 KO mice make it difficult to 
determine the role of this receptor in negative feedback of estradiol. In one study, 
gonadotrope specific ESR1 KO mice have normal levels of LH serum and Lhb mRNA 
(M C Gieske et al. 2008), suggesting minimal to no role in negative feedback of 
estradiol. In another study, gonadotrope specific ESR1 KO mice have high Lhb mRNA, 
albeit not as high as global ESR1 KO mice and E2 treatment does not repress Lhb 
mRNA to the degree that occurs in wild type mice, suggesting impaired negative 
feedback with loss of ESR1 at the level of the pituitary (Singh et al. 2009). However, it is 
possible that this loss of ESR1 at the pituitary may not directly impact Lhb mRNA 
transcription, but rather interfere with sensitivity to GnRH (Brown & McNeilly 1999). In 
all, it is interesting that E2 could decrease Lhb mRNA directly at the pituitary in culture, 
suggesting that there is something unique about the neonatal pituitary that allows this to 
happen. Another important observation is that regulation of Lhb mRNA in the neonatal 
pituitary is confined to females in culture. Perhaps, exposure to sex steroids through the 
testosterone surge programs the male pituitary to be unable to respond to estradiol 
directly at the pituitary, making males unable to decrease Lhb with E2 exposure 
(Clarkson & Herbison 2016). Females who were not previously exposed to sex steroids 
may be able to respond until they are also exposed to high sex steroids later in life, so 
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that as an adult, female pituitaries also do not respond to estradiol directly at the 
pituitary to directly regulate Lhb mRNA directly. The mechanism behind this is unknown 
and worthy of further exploration. 
Regulation of Fshb appears to be quite complicated as activation or inhibition of 
various receptors had somewhat contradictory results; E2 decreased expression in 
females, ICI decreased expression in males, E2+ICI had no effect, PPT, DPN, and the 
ED had no effect individually, but PPT+DPN increased Fshb in males and PPT, DPN, 
and the ED increased Fshb in males and females.  Unfortunately, no hints are given on 
the regulation of Fshb by examining the adult, estradiol does not seem to strongly 
regulate Fshb directly at the pituitary in the adult. In the adult, Fshb mRNA seems to be 
less regulated by estradiol levels than Lhb because ESR1 KO, ESR2 KO, and ESR1/2 
KO mice do not show differences in FSH plasma levels or Fshb mRNA (Couse et al. 
2003), showing that in the adult Fshb is more regulated by ovarian factors such as 
inhibin and activin (Couse et al. 2003). Pituitary gonadotrope specific ESR1 KO mice 
show no difference in Fshb mRNA or FSH serum levels (Mary C. Gieske et al. 2008). 
Similarly cultures of dispersed adult pituitary cells do not have changes in Fshb mRNA 
after 48hrs of estradiol exposure (Lindzey et al. 2006). Again, this demonstrates that the 
neonatal period may be unique in its ability for estradiol to regulate it. DES decreased 
Fshb levels in neonatal pituitary cultures, however sexes were not separated (Ishikawa 
et al. 2014). Interestingly, in our study we saw that E2 had no effect in males, however, 
ICI alone decreased Fshb in males. ICI has been shown to be able to activate GPER in 
other studies (Filardo et al. 2000; Y. Chen et al. 2014; Long et al. 2017). Therefore, if 
ICI is activating GPER, it is possible that in the neonatal pituitary ESR1 and ESR2 
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regulate Fshb mRNA differently than GPER. There are other documented cases where 
different estrogen receptors have opposite effects on gene transcription. For example, 
ESR1 activates cyclin D1 (Ccnd1) expression, whereas ESR2 inhibits its expression in 
HeLa cells (Liu et al. 2002). Similarly, ESR1 has been shown to activate transcription 
when complexed at AP-1 sites, whereas ESR2 inhibits transcription in reporter assays 
(Paech et al. 1997). One possibility is that ESR1 and ESR2 increase Fshb and GPER 
decreases Fshb so that in males it is balanced out and there is no overall effect with 
exposure to E2. In females, however, E2 suppressed Fshb and treatment with other 
compounds had no effect. Perhaps, the activation of GPER outweighs the activation of 
ESR1 or ESR2 in females. Additionally, it is possible that the GPER signaling leading to 
decreased Fshb may be found on the endoplasmic reticulum instead of the plasma 
membrane because the ED was unable to decrease Fshb in females or block the 
increase in Fshb in PPT, DPN, and ED cultures. However, it is clear that more studies 
are necessary to determine which receptors are important during this time period and 
how they regulate Fshb. 
We showed previously that Icam5 is suppressed by E2 directly at the pituitary in 
both males and females and this suppression is blocked by the ESR1/ESR2 antagonist 
ICI (Eckstrum et al. 2016). This suggests ESR1 and/or ESR2 are important in regulation 
of Icam5. Here we show that in females ESR1 activation was able to slightly decrease 
levels of Icam5 in females only, however, not to the extent that E2 was able to do. Only 
when all receptor agonists were added did we observe suppression of Icam5 in both 
males and females. In terms of what activation of all three receptors means for 
transcriptional regulation of Icam5, it suggests first of all, a multi-step process. 
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Membrane signaling through ESR1, ESR2 or GPER can lead to activation of kinases 
such as ERK/MAPK and PI3/AKT (Levin 2005). Kinases can then do several things. 
They can phosphorylate nuclear ER enhancing its transcriptional action (Kato et al. 
1995). They can influence the phosphorylation and recruitment of cofactors (Zwijsen et 
al. 1997). Additionally, they can activate or inhibit transcriptional regulators, leading to 
activation or inhibition of genes (Liang & Slingerland 2003). Here, we propose that 
membrane signaling activates a transcriptional repressor whose expression is increased 
by nuclear ERs, which then represses Icam5 transcription. This model is appealing to 
us because it takes 24hrs to see a decrease in Icam5 with E2 exposure (data not 
shown) and the translation inhibitor cycloheximide was able to inhibit the decrease in 
Icam5 caused by E2 (data not shown), suggesting a protein needed to be created in 
order to regulate Icam5. Additionally, there is no known putative ERE in the Icam5 
promoter, suggesting indirect mechanisms of regulation. However, further studies are 
necessary to determine the mechanism by which E2 regulates Icam5 mRNA. 
The purpose of E2 regulation of Icam5 and the reason multiple pathways impact 
mRNA levels is unknown. However, we hypothesize that ICAM5, which is expressed 
only in gonadotrope cells, may be important in coordinated hormone release of LH and 
FSH (Eckstrum et al. 2016). There is evidence in the adult that multiple signaling 
pathways regulate LH because in membrane only estrogen receptor alpha (MOER) and 
nuclear only estrogen receptor alpha (NOER) mice LH serum levels are elevated 
despite high levels of estradiol, indicating that both membrane and nuclear signaling are 
needed for suppression of LH serum levels (Pedram et al. 2014; Pedram et al. 2009). It 
could be that membrane and nuclear signaling are required to decrease Icam5 which 
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then decreases LH release and serum levels. Though MOER and NOER mice are 
globally affected so it may be due to changes in the hypothalamus instead of the 
pituitary. However, it is clear that both membrane and nuclear signaling are sometimes 
needed to regulate specific functions. In all, if Icam5 is regulated directly at the pituitary 
by nuclear and membrane signaling and if ICAM5 is involved in release of LH, it 
possible that the defects in NOER and MOER mice may be in part carried out by 
improper transcriptional repression of Icam5, which may impede the ability of E2 to 
decrease LH serum levels. 
At this point, the precise transcriptional mechanism by which Lhb, Fshb, and 
Icam5 are regulated remains unclear. It is very interesting that regulation of each of 
these transcripts appears unique even in so much as which estrogen receptors are 
important. This study highlights the necessity of studying the mechanism by which 
genes are regulated because it could differ even in genes that on the surface appear to 
be regulated similarly. It is also significant that there are age and sex specific effects 
with regard to regulation. Identification of how each of these genes are specifically 
regulated will provide insight into the effects of endocrine disrupting chemicals, which 
may preferentially bind one receptor versus another, leading to effects similar to that of 
estradiol, but not the exact same. Therefore, it is worth further investigation to clarify the 
precise mechanisms by which estradiol and compounds with estrogen-like effects 
decrease gene expression in the neonatal pituitary. 
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Figures and Tables 
 
Figure 13: Esr1 mRNA increased over the postnatal period whereas Esr2 mRNA 
decreased. Increased levels of Esr1 mRNA levels (A) and decreased levels Esr2 mRNA 
levels (B) in males (black) and females (grey) from postnatal day (PND)0 to adult 
(females in diestrus) compared to PND0 males. (*) indicates p ≤ 0.05 for males and 
females compared to PND0 male control. n=6-11. 
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Figure 14: Confirmation of estrogen receptor selective agonists. A dose response of 
ESR1 regulated Cckar levels showed increased Cckar at all doses of PPT (A) and DPN 
10-8M to 10-5M, but no increase at 10-9M (B). Membrane regulated Pmaip1 mRNA was 
decreased with exposure to the estrogen dendrimer (ED) in males but not in females 
(C). ED slightly increased Cckar (3-fold), however, E2 signaling is able to increase it 50-
fold (D). (*) indicates p ≤ 0.05.  n=3-6 (Cckar) n=9-10 (Pmaip1). 
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Figure 15: Lhb mRNA was decreased in females by combined ESR1 and ESR2 
activation. Co-treatment of E2+ICI blocked suppression of Lhb mRNA in females and 
ICI alone had no effects and no effect was seen in males with E2, E2+ICI, or ICI alone 
(A). PPT had no effect on Lhb mRNA in males or females (B). DPN had no effect on 
Lhb mRNA in males or females (C). ED had no effect on Lhb mRNA (D). Co-treatment 
of PPT and DPN had no effect in males, but decreased levels of Lhb mRNA in females 
similar to E2 (E). Treatment with PPT, DPN, and the ED had no effect on Lhb mRNA in 
males or females (F). (*) indicates p ≤ 0.05. n=7-13. 
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Figure 16: Fshb mRNA was regulated by receptor agonists in opposing ways. Co-
treatment of E2+ICI blocked suppression of Fshb mRNA in females and had no effect in 
males and ICI alone decreased Fshb mRNA in males but not in females (A). PPT had 
no effect on Fshb mRNA in males or females (B). DPN had no effect on Fshb mRNA in 
males or females (C). ED had no effect on Fshb mRNA in males or females (D). Co-
treatment of PPT and DPN increased Fshb mRNA in males and females (E). Treatment 
with PPT, DPN, and the ED increased levels of Fshb mRNA in males and females (F). 
(*) indicates p ≤ 0.05. n=7-13 
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Figure 17: Icam5 mRNA was decreased by nuclear and membrane signaling. PPT 
slightly decreased Icam5 mRNA in females, but not males (A). DPN did not change 
Icam5 mRNA levels in males or females (B). The ED did not change Icam5 mRNA in 
males or females (C).  Co-treatment of PPT and DPN did not alter Icam5 mRNA levels 
(D). Treatment with PPT, DPN, and the ED decreased levels of Icam5 mRNA in both 
males and females (F). (*) indicates p ≤ 0.05. n=7-13 
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Table 6: Summary of effects with different estrogen receptor ligands on Lhb, Fshb, and Icam5 mRNA.  Gene expression 
increased, decreased, or not changed (NC) via estradiol (E2), E2+ICI, ESR1, ESR2, membrane signaling, ESR1+ESR2, 
or ESR1, ESR2, and membrane signaling. 
 
Effects of ER selective agonists and antagonists on gene transcription 
Sex Gene E2 E2+ICI ICI ESR1 ESR2 Membrane ESR1+ESR2 ESR1+ESR2+ 
Membrane 
Male Lhb NC NC NC NC NC NC NC NC 
Female Lhb Decreased NC NC NC NC NC Decreased NC 
Male Fshb NC NC Decreased NC NC NC Increased Increased 
Female Fshb Decreased NC NC NC NC NC NC Increased 
Male Icam5 Decreased NC NC NC NC NC NC Decreased 
Female Icam5 Decreased NC NC Decreased NC NC NC Decreased 
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Chapter 5: Conclusions/Discussion 
Exposure to hormonal and chemical compounds is becoming an increasing 
problem with the rising production of chemicals. Unfortunately, some of these 
compounds have adverse effects on endocrine human health including obesity, 
reproductive disorders, and depression and/or anxiety (Vessey et al. 1983; Vandenberg 
et al. 2007). The pituitary is an integral component of the endocrine system and thus, 
disruption of the pituitary gland could potentially lead to the development of disorders 
caused by endocrine disrupting chemicals (EDCs). Many EDCs interfere with the action 
of naturally circulating hormones, including estrogen signaling. Bisphenol A is one of 
these compounds. It is one of the highest volume chemicals produced worldwide 
because it is found in many consumer products, which contain polycarbonate plastics 
and epoxy resins (Vandenberg et al. 2007). Because of its presence in so many 
products, it is hard to avoid exposure to this compound. BPA is found in human serum, 
urine, amniotic fluid, placental tissue, and umbilical cord blood (Vandenberg et al. 
2007), demonstrating that critical developmental periods may experience BPA 
exposure. Importantly, these developmental periods may be more sensitive to 
endocrine disruption and have the potential for lasting effects (Hanson & Gluckman 
2008). Because of the ubiquitous exposure to EDCs during critical windows of the 
development, it is important to understand what effect these compounds, as well as 
naturally circulating hormones, have on the pituitary. Characterization of the effects of 
naturally circulating hormones and exogenous exposure to E2 and BPA as well as the 
mechanisms by which these changes occur were analyzed in Chapters 2 through 4. 
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Sex differences in neonatal pituitary due to sex steroids 
In order to understand the potential effects of EDCs, like BPA, that can interfere 
with estrogen signaling, we first sought to determine the effects of naturally circulating 
hormones. Naturally circulating sex steroids are critical in the development of sex 
differences in the brain due to the testosterone surge that occurs in males. This 
testosterone is then converted to estradiol, which is the main hormone involved in 
masculinization of the brain (McCarthy 2008). We show that the neonatal pituitary also 
has sex differences in gene expression. Interestingly, these sex differences are 
confined to the gonadotrope lineage (Eckstrum et al. 2016). Females have higher levels 
of Lhb, Fshb, and Icam5 mRNA compared to the males and E2 exposure decreases 
expression of these genes. This demonstrates that the neonatal pituitary is sensitive to 
estrogen exposure and that sex differences in the HPG axis are apparent early, which 
may alter the ability of males or females to respond to external stimuli. Though it is 
interesting that only three genes were differentially expressed between males and 
females, it is possible that there are differences in protein levels, receptor activation, 
enzyme activity, etc. that were not examined in this study, which should be analyzed in 
more detail in the future to better understand the differences between males and 
females. 
BPA has sex specific and developmental window specific effects 
 Males and females do not always respond similarly to EDCs. In the embryonic 
period, BPA affected the females, but not the males. In the neonatal period, Pit1 mRNA 
was regulated in males, but not females and Pomc levels were decreased in females, 
but not males with 50 mg/kg/day BPA (Chapter 3), although the mechanism behind this 
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is unknown. The differences in the ability of males and females to respond to stimuli are 
likely due to natural sex differences established by the testosterone surge, which can 
potentially cause sensitization or desensitization. For example, females may be more 
sensitive to BPA than males during the embryonic period because males are exposed 
to higher testosterone levels beginning around embryonic day 13 (Clarkson & Herbison 
2016). Females, on the other hand, do not have high levels of circulating estrogen and 
estrogen that is circulating is bound by alpha-fetoprotein (Montano et al. 1995). 
Therefore, it is possible that the testosterone in males leads to desensitization of the 
pituitary to sex steroid hormonal signals.  Alternatively, it could be that due to higher 
levels of testosterone, BPA is less likely to bind receptors and have effects if it is 
competing with testosterone or estradiol.  BPA is not the only compound that can have 
sex specific effects. E2 can also have sex specific effects in that E2 decreases Lhb 
mRNA and Fshb mRNA in females only directly at the pituitary (Eckstrum et al. 2016), 
showing that there are innate differences in the male and female pituitary itself, without 
influence from the hypothalamus. This suggests that exposure to sex steroids may be 
able to sensitize or desensitize the pituitary, allowing for sex specific effects of EDCs to 
occur.  
Not only do males and females have different responses to BPA, but so do 
different developmental time periods. One of the major findings of our studies was that 
the embryonic and neonatal pituitaries do not appear to respond the same way to BPA 
exposure, demonstrating that there are differences between these two periods. Figure 
18 summaries the effects of BPA exposure in the embryonic and neonatal pituitary on 
the different lineages (Figure 18). In the embryonic pituitary, proliferation and the 
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gonadotrope lineage were the most affected, whereas in the neonatal period the PIT1 
and TPIT lineages were more affected by similar doses of BPA (Chapter 3). Again, we 
suggest the difference in embryonic versus neonatal changes may be due to natural 
hormones, which cause changes in the body leading to desensitization of some axes 
and sensitization of others. At birth, males have the testosterone surge, which is 
important in the generation of sex differences (Clarkson & Herbison 2016). Females do 
not have this surge, however, at 4 hours after birth, which is coincident with the 
testosterone surge, there are higher levels of free estradiol in females corresponding to 
free estradiol levels at proestrus (Montano et al. 1995). This increase in estradiol at birth 
could desensitize the HPG axis and proliferation in the neonatal female similarly to how 
embryonic testosterone may desensitize the male pituitary leading to a sex specific 
effects of embryonic BPA exposure. The reason for this increase, which also occurs in 
males, is not clear, however, it could be changes in isoforms of alpha-fetoprotein that 
bind estradiol more weakly or it could be due to an increase in glucocorticoids that 
occurs with birth, which alpha-fetoprotein also binds, making it so that there is more 
circulating estradiol (Vallette, Benassayag, Belanger, Nunez, & Jayle, 1977). 
Additionally, because glucocorticoids increase at birth, it is possible that they may play a 
role in either desensitizing the HPG axis, or sensitizing the TPIT and PIT1 lineages. 
Despite not knowing which factor or factors change from the embryonic to neonatal 
period leading to alternate effects in each period, it is clear that these two periods are 
not the same and thus, should not be overlooked when examining exposure to EDCs. 
Further experimentation needs to be done to determine which factors contribute to the 
ability of proliferation and the gonadotrope lineage to be altered in the embryonic 
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pituitary and not the neonatal pituitary and the ability of the TPIT and PIT1 lineages to 
be affected neonatally, but not embryonically. In the future, more extensive comparison 
of factors present in the embryonic and neonatal period may be useful in answering this 
question such as, receptor levels and activation, hormone levels, and gene or protein 
expression. Very little is known about the differences between these periods, however, 
these studies suggest that those differences may be very important in terms of 
sensitivity to EDCs. 
Taken together, BPA has sex specific and developmental window specific effects 
(summarized in Table 7) showing that the sexes are not the same, even at a very early 
age, and the developmental windows also are not the same. This demonstrates the 
importance of examining exposure to environmental compounds throughout 
development in both sexes as well as long after exposure, as compounds can sometime 
have lasting effects. 
The identification of a novel gene in the pituitary, Icam5, and its potential function and 
regulation 
One of the major findings of this study was the identification of Icam5. This 
molecule has never been described in the pituitary before. We showed that it is 
expressed specifically in the gonadotrope cells, however its function is not known. We 
hypothesize it may be involved in gonadotrope networks and potentially hormone 
release, due to its role in the brain. In the hippocampus, ICAM5 is expressed on the 
surface of dendritic filopodia, immature dendrite spines, and it makes connections with 
ICAM5 on other dendrites (Tian et al. 2000). The ability of ICAM5 to make homophilic 
connections with other ICAM5 molecules in the brain suggests that it may be able to do 
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the same in the pituitary. In the pituitary, all the different hormone secreting cell types 
form networks which allows the cells to function as a unit and coordinate hormone 
release (Bonnefont et al. 2005; Golan et al. 2016). In order for the cells to form these 
networks, they must be able to communicate with each other, potentially through 
various adhesion molecules. Because ICAM5 is only present in gonadotrope cells, it is 
possible that ICAM5 is the cell adhesion molecule important in forming functional 
gonadotrope networks allowing for coordinated pulsatile release of LH and FSH. 
Therefore, the lower serum levels of LH and FSH seen in male mice after the 
testosterone surge (Poling & Kauffman 2012) may be not only due to decreased Lhb 
and Fshb transcription itself, but also due to less Icam5 leading to less coordinated 
hormone release. In the future, determining the role of ICAM5 will be a necessity. 
Analysis of ICAM5 in a pre-gonadotrope cell line, alpha T3 cells, which expresses 
Icam5 may be useful to determine if disruption of ICAM5 alters the ability of these cells 
to connect and move. This would be able to tell us if ICAM5 is important in forming 
gonadotrope networks. Furthermore, to determine if ICAM5 is important in coordinated 
hormone release, pituitary cultures using siRNA to suppress Icam5 can be done and the 
release of LH and FSH in the media could be measured.  
Though the effect of ICAM5 on reproductive status is unknown, it is possible it 
can disrupt synchronized LH and FSH secretion and thus fertility. Interestingly, in 
gonadotrope specific ESR1 knockout mice Lhb and Fshb mRNA are not altered. 
Additionally, basal levels of LH and FSH serum are maintained, however, these mice 
still exhibit infertility and irregular estrous cyclicity suggesting a disorder in properly 
regulating LH and FSH release (M C Gieske et al. 2008). It is possible that ICAM5 may 
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be disrupted in these gonadotrope specific ESR1 knockout mice leading to a disruption 
of synchronized secretion of LH and FSH. Examination of ICAM5 knockout mice would 
elucidate the function and determine if there is any reproductive outcome on loss of this 
protein. 
Mechanisms of estrogen regulation 
Finally, to understand how potentially estrogenic EDCs can influence the 
pituitary, we really need to understand the mechanism by which estrogen itself 
regulates transcription in the pituitary. To start, we have examined briefly the 
mechanisms of estradiol regulation of sexually dichotomous genes Lhb, Fshb, and 
Icam5 in the neonatal pituitary. Interestingly, each gene is regulated somewhat 
differently than the next, which exemplifies the diversity of estrogen signaling. In 
females, Lhb appears to be regulated by ESR1 and ESR2, whereas Fshb appears to be 
regulated by all receptors in opposing ways. ESR1 and ESR2 appear to increase Fshb, 
however, E2 decreases it in females, suggesting GPER may be responsible for the 
decrease in Fshb. Despite this, Lhb and Fshb mRNA actually appear to be more 
strongly regulated in vivo than directly at the pituitary, suggesting regulation of these 
genes directly at the pituitary may be minimal. In fact, Lhb and Fshb mRNA were not 
regulated in males directly at the pituitary by E2. If Lhb and Fshb are not strongly 
regulated by estrogen signaling directly at the pituitary, it may be by contributing to the 
difficulty in determining the mechanism of regulation directly at the pituitary. More 
importantly, it would suggest that in vivo changes of Lhb and Fshb due to exposure to 
EDCs would be more likely to be due to systemic effects, such as effects on the 
hypothalamus, leading to changes in GnRH. However, more experiments to determine 
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the role of GPER may be worth-while, at least to explain our data and to see if any 
combination of selective agonist can result in a decrease similar to E2 in females. G1 is 
a selective agonist for GPER and should be examined in our culture system. 
Because Icam5 is a novel gene in the pituitary and is regulated by both E2 and 
BPA (Eckstrum et al. 2016), determining how it is regulated is incredibly important and 
likely to be a focus of the lab in the future. We saw that E2 can decrease expression of 
Icam5 in vivo and directly at the pituitary. ICI was able to block this effect, suggesting 
that ESR1, ESR2, or both are important in regulation of this gene directly at the 
pituitary. Further analysis, however, demonstrated that it is not that simple and 
activation of ESR1, ESR2, and membrane signaling were all needed to decrease 
Icam5, suggesting that regulation of Icam5 may require multiple steps and ablation of 
any one of those steps may limit the ability of the regulation to occur. We have only 
begun to scratch the surface on how this gene is regulated, but we hypothesize a two-
step process in which nuclear ESR1 activates transcription of a transcriptional repressor 
shown in figure 19. Then, in order for this repressor to become activated, it must be 
phosphorylated by membrane signaling through kinase cascades, possibly through 
GPER. The phosphorylated receptor would then bind to the regulatory element of Icam5 
and inhibits its transcription. ESR1 may be the nuclear estrogen receptor responsible for 
the increase in a transcriptional repressor because activation of ESR1 by PPT was able 
to slightly decrease Icam5 in females. Next, we hypothesize that the transcriptional 
repressor, may be CREB, which is known to regulate transcription of gonadotrope 
genes and be regulated by E2 exposure (Iqbal et al. 2007). Additionally, Icam5 
possesses putative CREB transcription factor binding sites suggesting CREB may pay a 
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role in its regulation (unpublished observation). However, at this point all we can do is 
speculate about the potential regulatory element. To narrow, our focus it would be 
helpful to find the precise regulatory region using promoter deletion analysis. These can 
potentially be done in the pre-gonadotrope cell line, alpha T3 cells, however, they have 
not been done yet due to E2 being unable to regulate Icam5 in these cells, suggesting 
they are missing some necessary factor. In fact, they have low levels of Esr2 and Gper1 
mRNA (the mRNA for GPER, unpublished observations).  
We have determined that membrane signaling is likely important in transcription 
of Icam5, however, this does not say which receptor at the membrane is important. 
GPER is a membrane bound receptor, which can be located in the plasma membrane. 
However, ESR1 and ESR2 have also been shown to associate with the membrane in 
other studies (Zarate et al. 2012; Filardo & Thomas 2012). We suspect that GPER may 
be important because PPT should be able to activate membrane ESR1 as well as 
nuclear and we did not see the same degree of suppression with PPT treatment as we 
did with PPT+DPN+ED. Clearly, more studies are needed to determine the precise 
mechanism by which these genes are regulated. Determining the mechanism by which 
these genes are regulated will be very important in understanding how endocrine 
disrupting chemicals disrupt endocrine physiology. If all these genes are regulated 
differently, it is possible that different EDCs would have different effects based on which 
specific receptors are bound with higher affinity in specific contexts.  
Effects of neonatal exposure to BPA, are they dangerous? 
Exposure to EDCs such as BPA during the neonatal time period, which equates 
to the third trimester of human development, has the potential to adversely impact 
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several aspects of the endocrine system. We saw that neonatal exposure to BPA 
decreased Pit1, Pomc, and Icam5 expression in a dose and sex specific manner 
(Chapter 3, (Eckstrum et al. 2016)). Pit1 was decreased by low doses of BPA (0.05 and 
0.5µg/kg/day) in males, Pomc was decreased by higher doses of BPA (0.5 in males and 
0.5 and 50µg/kg/day in females), and Icam5 was decreased by much higher doses of 
BPA (50mg/kg/day in females) (Table 1). The differences in the concentrations of BPA 
needed to effect each of these genes may again give insight into how sensitive these 
axes are. For example, the PIT1 and TPIT lineages may be more sensitive to BPA 
during the neonatal period because less BPA was needed to have an effect than was 
needed to reduce Icam5. Nevertheless, these data show that under the right conditions, 
BPA can alter expression of each of the lineages. Because we did not see any 
corresponding changes in protein, it is difficult to state the potential adverse effects that 
may occur due to our dosing paradigm. The reasons we didn’t see any changes in 
protein expression could be the time we took them after dosing or the age that they 
were taken. We also did not analyze serum levels of pituitary hormones, so if BPA alters 
secretion, then we would have missed it. Future studies examining hormone levels of 
pituitary peptides may be useful to determine if hormone release is altered by neonatal 
BPA exposure. Despite our inability to draw a definitive conclusion on the adverse 
effects of neonatal BPA exposure due to our data alone, in other studies using different 
doses, timing of exposure, duration of exposure, or age of analysis, all of the endocrine 
axes have been altered under some conditions. Neonatal BPA treatment in rats, 
reduced the ability of the pituitary to release LH in response to GnRH in the adult 
(Fernandez et al. 2009), increased pituitary GH content at 5 months (Ramirez et al. 
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2012), and increased PRL serum at PND30 (Khurana et al. 2000). Additionally, 
perinatal exposure increased ACTH and glucocorticoids in males (F. Chen et al. 2014). 
Therefore, it is likely that neonatal exposure to BPA has many adverse effects on the 
endocrine system and perhaps further examination of different ages and different 
parameters would show some of these effects.  
Final conclusions 
Our studies to determine the effects of neonatal exposure to E2 and BPA have 
discovered many things to increase our understanding of neonatal pituitary 
development as well as point out many items that still need to be discovered. Only 
recently have people begun to study the neonatal period of pituitary development and 
very little is known about the effects of hormonal or chemical stimuli on this period. Our 
studies show that the neonatal period is sensitive to hormonal and chemical exposure, 
however, this sensitivity is different than the embryonic and adult periods. We observed 
changes in gene expression with exposure to E2 and BPA and suggest that some axes 
in the neonatal pituitary are more sensitive than others. There are also sex differences 
and sex specific effects in this period, showing males and females are not that similar, 
even before puberty. In addition to the uniqueness of the neonatal pituitary, we also 
observed that estrogenic regulation of each gene in the pituitary is unique, 
demonstrating the diversity of ways estrogens can alter the pituitary. 
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Figures and Tables 
 
Figure 18: Summary of effects of BPA on critical windows of pituitary development. Low 
doses (0.5 and 50µg/kg/day) of BPA exposure during the embryonic period alter the 
progenitor cells and gonadotrope lineage while neonatal BPA exposure alters the PIT1 
and TPIT lineages. Embryonic effects (blue), neonatal effects (red), MSH=melanotropin 
stimulating hormone, ACTH= Adrenocorticotropic hormone, GH= growth hormone, 
TSH= thyroid stimulating hormone, PRL= prolactin, LH= luteinizing hormone, FSH= 
follicle stimulating hormone. 
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Embryonic and neonatal effects on pituitary development 
Period Lineage Sex Cell number Transcription 
Embryonic Progenitors Male NC NC 
  Female Increased 
Ki67 
Increased mKi67 
 NR5A1 Male NC NC 
  Female Increased Increased Lhb (BPA0.5), 
Decreased Lhb (BPA50) 
 TPIT Male NA NC (Pomc) 
  Female  NA NC (Pomc) 
 PIT1 Male NA NC (Gh, Tshb) 
  Female NA NC (Gh, Tshb) 
Neonatal Progenitors Male NA NC 
  Female NA NC 
 NR5A1 Male NA NC (Nr5a1, Lhb) 
  Female NA NC (Nr5a1, Lhb) 
Decreased Icam5 (BPA 
50mg) 
 TPIT Male NA Decreased Pomc 
(BPA0.5) 
  Female NC (POMC) Decreased Pomc 
(BPA0.5, BPA50) 
 PIT1 Male NC Decreased Pit1 
(BPA0.05, BPA0.5) 
  Female NA NC (Pit1, Gh, Tshb, Prl) 
 
Table 7: Summary of BPA effects during the embryonic and neonatal period. BPA 
exposure altered embryonic and neonatal as well as male and female pituitaries 
differently. The effects are summarized showing differences in cell numbers changed in 
the embryonic and neonatal period as well as transcriptional changes. NA=not analyzed 
NC=not changed. 
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Figure 19: Proposed model of Icam5 regulation. We hypothesize that nuclear ER 
signaling increases transcription of a transcriptional repressor (TR) which then is 
phosphorylated (P) via the activation of membrane signaling from an estrogen receptor 
(ER). The activated phosphorylated receptor then can bind to the Icam5 promoter and 
inhibit transcription.  
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Abbreviations: 
ACTH- adreno-corticotropic hormone 
ADH- anti-diuretic hormone 
AHR- aryl hydrocarbon receptor 
AL- Anterior lobe 
AP-1- activator protein 1 
AVPV- anteroventral periventricular nucleus 
BMP- brain morphogenetic protein 
BPA- bisphenol A 
BSA-bovine serum albumin 
Cckar- cholecystokinin A receptor 
Cdk4- cyclin-dependent kinase 4 
ChIP- chromatin immunoprecipitation 
CREB-cAMP response element binding protein 
CRH- corticotropin releasing hormone 
DES- diethylstilbestrol 
DPN-diarylpropionitrile- ESR2 agonist 
e- embryonic day 
E2- estradiol 
ED- estrogen dendrimer  
EDC- endocrine disrupting chemical 
EGR1- early growth response 1 
ER- estrogen receptor 
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ERE- estrogen response element 
ERM- ezrin/radixin/moesin 
ESR1-estrogen receptor alpha 
ESR2-estrogen receptor beta 
FGF- fibroblast growth factor 
Foxl2-forkhead box L2 
FSH- follicle stimulating hormone 
GDNF- glial cell line-derived neurotrophic factor 
GFRa2- glial cell line-derived neurotrophic factor receptor alpha 
GH- growth hormone 
GHRH- growth hormone releasing hormone 
GHRHR- growth hormone releasing hormone receptor 
GnRH- gonadotropin releasing hormone 
GPER- G protein coupled estrogen receptor 
GPR54- Kiss1r- G-protein coupled receptor 54, kisspeptin receptor 
GR- glucocorticoid receptor 
Hes1- hairy and enhancer of split 1 
HPA- hypothalamic-pituitary-adrenal 
HPG-Hypothalamic-pituitary-gonadal 
hpg- Hypogonadal mice 
HPT- hypothalamic- pituitary- thyroid 
ICAM5-intercellular adhesion molecule 5 
IL- intermediate lobe 
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KO- knockout 
LH- luteinizing hormone 
LOAEL- lowest observed adverse effect level 
MSH- melanotropin stimulating hormone 
NF-κβ- nuclear factor kappa-light-chain-enhancer of activated B cells 
OCT4- octamer-binding transcription factor 4 
OT- oxytocin 
PIT1 (POU1F1)- POU domain, class 1, transcription factor 1 
Pitx2- paired-like homeodomain 2 
PL-posterior lobe 
PND- postnatal day 
POMC- pro-opiomelanocortin 
PPT- propyl-pyrazole-triol-ESR1 agonist 
PRL- prolactin 
RBPJ- recombining binding protein suppressor of hairless 
RIA-Radioimmunoassay 
SAGE- serial analysis gene expression 
SF1- steroidogenic factor 1 
SHH- sonic hedgehog 
SOX2- SRY (sex determining region Y)-box 2 
TGFβ- transforming growth factor 
TH- tyrosine hydroxylase  
TPIT (TBX19)- T-box transcription factor 
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TRH- thyrotropin releasing hormone 
TSH- thyroid stimulating hormone 
UGT- uridine diphosphate glucuronosyltransferase 
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